1
|
Tchalova K, Lydon JE, Atkinson L, Fleming AS, Kennedy J, Lecompte V, Meaney MJ, Moss E, O'Donnell KA, O'Donnell KJ, Silveira PP, Sokolowski MB, Steiner M, Bartz JA. Variation in the mu-opioid receptor gene (OPRM1) moderates the influence of maternal sensitivity on child attachment. Transl Psychiatry 2024; 14:181. [PMID: 38580654 PMCID: PMC10997775 DOI: 10.1038/s41398-024-02888-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Revised: 03/15/2024] [Accepted: 03/20/2024] [Indexed: 04/07/2024] Open
Abstract
The endogenous opioid system is thought to play an important role in mother-infant attachment. In infant rhesus macaques, variation in the μ-opioid receptor gene (OPRM1) is related to differences in attachment behavior that emerges following repeated separation from the mother; specifically, infants carrying at least one copy of the minor G allele of the OPRM1 C77G polymorphism show heightened and more persistent separation distress, as well as a pattern of increased contact-seeking behavior directed towards the mother during reunions (at the expense of affiliation with other group members). Research in adult humans has also linked the minor G allele of the analogous OPRM1 A118G polymorphism with greater interpersonal sensitivity. Adopting an interactionist approach, we examined whether OPRM1 A118G genotype and maternal (in)sensitivity are associated with child attachment style, predicting that children carrying the G allele may be more likely to develop an ambivalent attachment pattern in response to less sensitive maternal care. The sample consisted of 191 mothers participating with their children (n = 223) in the Maternal Adversity, Vulnerability and Neurodevelopment (MAVAN) project, a community-based, birth cohort study of Canadian mothers and their children assessed longitudinally across the child's development. Maternal sensitivity was coded from at-home mother-child interactions videotaped when the child was 18 months of age. Child attachment was assessed at 36 months using the Strange Situation paradigm. As predicted, G allele carriers, but not AA homozygotes, showed increasing odds of being classified as ambivalently attached with decreasing levels of maternal sensitivity. Paralleling earlier non-human animal research, this work provides support for the theory that endogenous opioids contribute to the expression of attachment behaviors in humans.
Collapse
Affiliation(s)
- K Tchalova
- Department of Psychology, McGill University, Montréal, QC, Canada
| | - J E Lydon
- Department of Psychology, McGill University, Montréal, QC, Canada
| | - L Atkinson
- Department of Psychology, Toronto Metropolitan University, Toronto, ON, Canada
| | - A S Fleming
- Department of Psychology, University of Toronto Mississauga, Toronto, ON, Canada
| | - J Kennedy
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - V Lecompte
- L'Université du Québec à Montréal, Montréal, QC, Canada
| | - M J Meaney
- Department of Psychology, McGill University, Montréal, QC, Canada
- Douglas Research Centre, Montréal, QC, Canada
- Singapore Institute for Clinical Sciences, A*STAR, Singapore, Singapore
| | - E Moss
- L'Université du Québec à Montréal, Montréal, QC, Canada
| | - K A O'Donnell
- Yale School of Medicine, Yale University, New Haven, CT, USA
| | - K J O'Donnell
- Department of Psychology, Simon Fraser University, Burnaby, BC, Canada
| | - P P Silveira
- Department of Psychiatry, McGill University, Montréal, QC, Canada
| | - M B Sokolowski
- Department of Ecology and Evolutionary Biology, University of Toronto, Toronto, ON, Canada
| | - M Steiner
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - J A Bartz
- Department of Psychology, McGill University, Montréal, QC, Canada.
| |
Collapse
|
2
|
Esteban-Ortega M, Steiner M, Andreu-Vázquez C, Thuissard-Vasallo I, Díaz-Rato A, Muñoz-Fernández S. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis. J Clin Med 2024; 13:1402. [PMID: 38592203 PMCID: PMC10933845 DOI: 10.3390/jcm13051402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/22/2024] [Accepted: 02/25/2024] [Indexed: 04/10/2024] Open
Abstract
BACKGROUND The aim of this study was to describe the characteristics of patients with uveitis associated with an immunologic or idiopathic disease that requires immunosuppressive treatment and the response to such treatments in real clinical practice. METHODS An observational, descriptive, longitudinal, and retrospective study of a cohort of patients diagnosed with noninfectious uveitis was performed. To assess the response to treatment, we evaluated the change in visual acuity, vitritis, and the presence of macular edema. RESULTS We included 356 patients. Overall, 12% required treatment with systemic corticosteroids, and 66 patients (18.5%) required immunosuppressive/biological treatment, with methotrexate being the most used (55%). Immunosuppressive drugs were used in 59 cases (in 56 patients, as the first choice of treatment and for 3 patients as the second choice after treatment with biologics). Treatment with biologics was the first choice in 10 patients out of 66 (15%), and 34 (48%) required them at some time during the disease, with adalimumab being the most commonly used. Thirty-five patients (53%) needed to switch drugs due to a lack of response to the first one. There were no differences between different drugs in the resolution of vitritis and improvement in vision. CONCLUSIONS The use of systemic corticosteroids and immunosuppressive/biologics was necessary for a high number of patients with noninfectious uveitis. In our series, tocilizumab was significantly more effective in the resolution of macular edema.
Collapse
Affiliation(s)
- Mar Esteban-Ortega
- Department of Ophthalmology, Infanta Sofía University Hospital, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain;
| | - Martina Steiner
- Department of Rheumatology, Infanta Sofía University Hospital, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain; (M.S.); (S.M.-F.)
| | - Cristina Andreu-Vázquez
- Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea, 28702 Madrid, Spain; (C.A.-V.); (I.T.-V.)
| | - Israel Thuissard-Vasallo
- Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea, 28702 Madrid, Spain; (C.A.-V.); (I.T.-V.)
| | - Alvaro Díaz-Rato
- Department of Ophthalmology, Infanta Sofía University Hospital, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain;
| | - Santiago Muñoz-Fernández
- Department of Rheumatology, Infanta Sofía University Hospital, FIIB HUIS HHEN, Universidad Europea, 28702 Madrid, Spain; (M.S.); (S.M.-F.)
| |
Collapse
|
3
|
Romero-Bogado L, Steiner M, Thuissard Vasallo IJ, Andreu Vázquez C, Navío T, Muñoz-Fernández S. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases. Med Clin (Barc) 2024:S0025-7753(24)00028-9. [PMID: 38418311 DOI: 10.1016/j.medcli.2023.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 12/02/2023] [Accepted: 12/05/2023] [Indexed: 03/01/2024]
Abstract
OBJECTIVE To determine the seroprevalence of SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMID) treated with biologic (bDMARDs) or synthetic targeted disease-modifying antirheumatic drugs (tsDMARDs). METHODS An observational, descriptive, prospective and cross-sectional study of analytical prevalence analysis was conducted in patients with IMID with bDMARDs or tsDMARDs. Seroprevalence was compared by measuring immunoglobulinG (IgG) against SARS-CoV-2 between October/2020 and May/2021. RESULTS A total of 550 IMID's patients were studied, all of them on treatment with bDMARDs or tsDMARDs. The seroprevalence of the total patient group was 16% (88/550). Patients receiving therapy with tumor necrosis factor alpha inhibitors (TNFi) had a higher seroprevalence compared to other biologic and synthetic targeted therapies (OR: 1.792 [95%CI: 1.088-2.951]; P=.021). The influence on seroprevalence of concomitant use with b/tsDMARDs of conventional synthetic DMARDs (csDMARDs) was also analyzed. A lower seroprevalence was demonstrated in the group of patients treated with TNFi and methotrexate together, compared with those on TNFi monotherapy, 10.1 vs 24.1% (OR: 0.355 [95%CI: 0.165-0.764]; P=.006). No significant differences were found with the other DMARDs. Regarding IMIDs, no differences in seroprevalence were identified between the different disease groups. CONCLUSION Patients on treatment with TNFα inhibitors have better humoral response compared to the other b/tsDMARDs. However, when associated with methotrexate the seroprevalence decreases significantly.
Collapse
Affiliation(s)
- Liz Romero-Bogado
- Sección de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, San Sebastián de los Reyes, Madrid, España.
| | - Martina Steiner
- Sección de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, San Sebastián de los Reyes, Madrid, España
| | | | - Cristina Andreu Vázquez
- Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España
| | - Teresa Navío
- Sección de Reumatología, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, España
| | - Santiago Muñoz-Fernández
- Sección de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid, San Sebastián de los Reyes, Madrid, España
| |
Collapse
|
4
|
Paredes-Romero MB, Castañeda-Estévez E, Steiner M, Cobo-Ibáñez T, Esteban-Vázquez A, Muñoz-Fernández S. Raynaud's phenomenon and digital ischaemia induced by ixekizumab. Rheumatology (Oxford) 2024; 63:e3-e5. [PMID: 37280057 DOI: 10.1093/rheumatology/kead270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 05/11/2023] [Accepted: 05/26/2023] [Indexed: 06/08/2023] Open
Affiliation(s)
- M Beatriz Paredes-Romero
- Rheumatology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
- Universidad Europea de Madrid, Madrid, Spain
| | | | - Martina Steiner
- Rheumatology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
- Universidad Europea de Madrid, Madrid, Spain
| | - Tatiana Cobo-Ibáñez
- Rheumatology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
- Universidad Europea de Madrid, Madrid, Spain
| | - Ana Esteban-Vázquez
- Rheumatology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
| | - Santiago Muñoz-Fernández
- Rheumatology Department, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
- Universidad Europea de Madrid, Madrid, Spain
| |
Collapse
|
5
|
Rametov NM, Steiner M, Bizhanova NA, Abdel ZZ, Yessimseit DT, Abdeliyev BZ, Mussagalieva RS. Mapping Plague Risk Using Super Species Distribution Models and Forecasts for Rodents in the Zhambyl Region, Kazakhstan. Geohealth 2023; 7:e2023GH000853. [PMID: 37965638 PMCID: PMC10641984 DOI: 10.1029/2023gh000853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 10/21/2023] [Accepted: 10/24/2023] [Indexed: 11/16/2023]
Abstract
One of the most extensive natural plague centers, or foci, is located in Central Asia, in particular, the Zhambyl region in Southern Kazakhstan. Here, we conducted plague surveillance from 2000 to 2020 in the Zhambyl region in Kazakhstan and confirmed 3,072 cases of infected wild animals. We used Species Distribution Modeling by employing MaxEnt, and identified that the natural plague foci are primarily located in the Moiynqum, Betpaqdala, and Tauqum Deserts. The Zhambyl region's central part, including the Moiynqum and Sarysu districts, has a high potential risk of plague outbreak for the rural towns and villages. Since the phenomenon of climate change has been identified as a determinant that affects the rodent populations, thereby elevating the likelihood of an outbreak of plague, we investigated the potential dissemination routes of the disease under the changing climate conditions, thus creating Species Distribution Forecasts for the rodent species in southern part of Kazakhstan for the year 2100. By 2100, in case of increasing temperatures, the range of host species is likely to expand, leading to a higher risk of plague outbreaks. The highest risk of disease transmission can be expected at the outer limits of the modeled total distribution range, where infection rates are high, but antibody presence is low, making many species susceptible to the pathogen. To mitigate the risk of a potential plague outbreak, it is necessary to implement appropriate sanitary-epidemiological measures and climate mitigation policies.
Collapse
Affiliation(s)
- N. M. Rametov
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
- Institute of IonosphereAlmatyKazakhstan
- Department of Geospatial EngineeringSatpaev Kazakh National Research Technical UniversityAlmatyKazakhstan
| | - M. Steiner
- Department of Animal ScienceWageningen University and ResearchWageningenThe Netherlands
| | - N. A. Bizhanova
- Laboratory of TheriologyInstitute of ZoologyAlmatyKazakhstan
- Department of Biodiversity and BioresourcesAl‐Farabi Kazakh National UniversityAlmatyKazakhstan
- Wildlife Without Borders Public FundAlmatyKazakhstan
| | - Z. Zh. Abdel
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - D. T. Yessimseit
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - B. Z. Abdeliyev
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| | - R. S. Mussagalieva
- National Scientific Center for Particularly Dangerous Infections named after M. AikimbaevAlmatyKazakhstan
| |
Collapse
|
6
|
Esteban-Vazquez A, Steiner M, Castañeda E, Andreu-Vazquez C, Thiussard IJ, Somodevilla A, Gracia-Martínez M, Sánchez-Diaz R, García-Yubero C, Paredes-Romero MB, Munoz-Fernández S. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors. Vaccines (Basel) 2023; 11:1610. [PMID: 37897012 PMCID: PMC10610564 DOI: 10.3390/vaccines11101610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 10/11/2023] [Accepted: 10/16/2023] [Indexed: 10/29/2023] Open
Abstract
Background. The risk of herpes zoster reactivation is increased in immunocompromised patients, especially in those with immune-mediated inflammatory diseases (IMIDs) on Janus kinase inhibitor (JAKi) treatment. The recombinant subunit herpes zoster vaccine (RZV) is a non-live vaccine, recently approved for this subgroup of patients, which shows high rates of vaccine effectiveness, with few adverse effects reported in clinical trials. Purpose. The aim of this real-world study was to determine the immunogenicity and safety of RZV in IMID patients on JAKi treatment. Methods. The increase in the concentration of anti-gE antibody for varicella zoster virus post-vaccination, compared to the pre-vaccination concentration, was analyzed to test the humoral immune response. Adverse effects after the first and second vaccine doses were registered. Results. In total, 49 patients were analyzed, and a fourfold increase in antibody concentration was achieved in almost 40% of subjects, with only one serious local adverse effect. Discussion. The resulting immunogenicity was lower than that observed in clinical trials, probably due to the presence of immune disease and immunosuppressive treatment, and to the fact that this was a real-world study. No differences in response according to age, previous virus zoster reactivation, or concomitant treatments were found. Conclusions. RZV was well tolerated and reached the immune response objective in 40% of patients. These results reinforce the importance of including RZV vaccination for immunosuppressed patients. Real-world studies regarding vaccine effectiveness are still needed in order to gain a full understanding of the response to RZV in this group of patients.
Collapse
Affiliation(s)
- Ana Esteban-Vazquez
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
- Statistics Deparment, Universidad Europea, 28703 Madrid, Spain; (C.A.-V.); (I.J.T.)
- Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), 28702 Madrid, Spain
| | - Martina Steiner
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
- Statistics Deparment, Universidad Europea, 28703 Madrid, Spain; (C.A.-V.); (I.J.T.)
- Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), 28702 Madrid, Spain
| | - Elisabet Castañeda
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
| | | | - Israel J. Thiussard
- Statistics Deparment, Universidad Europea, 28703 Madrid, Spain; (C.A.-V.); (I.J.T.)
| | | | - Moisés Gracia-Martínez
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
| | - Rosa Sánchez-Diaz
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
| | | | - Maria Beatriz Paredes-Romero
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
- Statistics Deparment, Universidad Europea, 28703 Madrid, Spain; (C.A.-V.); (I.J.T.)
| | - Santiago Munoz-Fernández
- Rheumatology Department, Infanta Sofía University Hospital, 28703 Madrid, Spain; (M.S.); (E.C.); (M.G.-M.); (R.S.-D.); (M.B.P.-R.); (S.M.-F.)
- Statistics Deparment, Universidad Europea, 28703 Madrid, Spain; (C.A.-V.); (I.J.T.)
- Infanta Sofia University Hospital and Henares University Hospital Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN), 28702 Madrid, Spain
| |
Collapse
|
7
|
Steiner M, Baur H, Blasimann A. Sex-specific differences in neuromuscular activation of the knee stabilizing muscles in adults - a systematic review. Arch Physiother 2023; 13:4. [PMID: 36788637 PMCID: PMC9930324 DOI: 10.1186/s40945-022-00158-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 12/21/2022] [Indexed: 02/16/2023] Open
Abstract
INTRODUCTION The rupture of the anterior cruciate ligament (ACL) is one of the most common injuries of the knee. Women have a higher injury rate for ACL ruptures than men. Various indicators for this sex-specific difference are controversially discussed. AIM A systematic review of the literature that compares surface electromyography (EMG) values of adult female and male subjects to find out if there is a difference in neuromuscular activation of the knee stabilizing muscles. METHODS This systematic review has been guided and informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Studies which examined sex-specific differences with surface EMG measurements (integral, root mean squares, mean values, analysis of time and amplitude) of the knee stabilizing muscles were retrieved via searches from the databases PubMed, CINAHL, Embase, CENTRAL and SPORTDiscus. The risk of bias of included studies was assessed with the National Heart, Lung and Blood Institute (NHLBI) study quality assessment tool. A synthesis of results was performed for relevant outcomes. RESULTS Fifteen studies with 462 healthy participants, 233 women (mean age 21.9 (± 2.29) years) and 299 men (mean age 22.6 (± 2.43) years), were included in the systematic review. The methodological quality of the studies was mostly rated "fair" (40%). A significantly higher activity of the muscles vastus lateralis and vastus medialis was found in females, in three studies. Two studies found significantly lower neuromuscular activity in the muscles biceps femoris and semitendinosus in females. All other included studies found no significant differences or reported even contradicting results. CONCLUSION The controversial findings do not allow for a concluding answer to the question of a sex-specific neuromuscular activation. Further research with higher statistical power and a more homogeneous methodical procedure (tasks and data normalisation) of the included studies may provide insight into possibly existing sex-specific differences in neuromuscular activation. This systematic review could help to improve the methodical design of future studies to get a more valid conclusion of the issue. TRIAL REGISTRATION CRD42020189504.
Collapse
Affiliation(s)
- Martina Steiner
- Division of Physiotherapy, Bern University of Applied Sciences, School of Health Professions, Bern (CH), Switzerland.
| | - Heiner Baur
- grid.424060.40000 0001 0688 6779Division of Physiotherapy, Bern University of Applied Sciences, School of Health Professions, Bern (CH), Switzerland
| | - Angela Blasimann
- grid.424060.40000 0001 0688 6779Division of Physiotherapy, Bern University of Applied Sciences, School of Health Professions, Bern (CH), Switzerland ,grid.5284.b0000 0001 0790 3681Faculty of Medicine and Health Sciences, Department of Rehabilitation Sciences and Physiotherapy, University of Antwerp, Wilrijk (BE), Belgium
| |
Collapse
|
8
|
Evans RA, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Aul R, Beirne P, Bolton CE, Brown JS, Choudhury G, Diar-Bakerly N, Easom N, Echevarria C, Fuld J, Hart N, Hurst J, Jones MG, Parekh D, Pfeffer P, Rahman NM, Rowland-Jones SL, Shah AM, Wootton DG, Chalder T, Davies MJ, De Soyza A, Geddes JR, Greenhalf W, Greening NJ, Heaney LG, Heller S, Howard LS, Jacob J, Jenkins RG, Lord JM, Man WDC, McCann GP, Neubauer S, Openshaw PJM, Porter JC, Rowland MJ, Scott JT, Semple MG, Singh SJ, Thomas DC, Toshner M, Lewis KE, Thwaites RS, Briggs A, Docherty AB, Kerr S, Lone NI, Quint J, Sheikh A, Thorpe M, Zheng B, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Harrison EM, Wain LV, Brightling CE, Abel K, Adamali H, Adeloye D, Adeyemi O, Adrego R, Aguilar Jimenez LA, Ahmad S, Ahmad Haider N, Ahmed R, Ahwireng N, Ainsworth M, Al-Sheklly B, Alamoudi A, Ali M, Aljaroof M, All AM, Allan L, Allen RJ, Allerton L, Allsop L, Almeida P, Altmann D, Alvarez Corral M, Amoils S, Anderson D, Antoniades C, Arbane G, Arias A, Armour C, Armstrong L, Armstrong N, Arnold D, Arnold H, Ashish A, Ashworth A, Ashworth M, Aslani S, Assefa-Kebede H, Atkin C, Atkin P, Aung H, Austin L, Avram C, Ayoub A, Babores M, Baggott R, Bagshaw J, Baguley D, Bailey L, Baillie JK, Bain S, Bakali M, Bakau M, Baldry E, Baldwin D, Ballard C, Banerjee A, Bang B, Barker RE, Barman L, Barratt S, Barrett F, Basire D, Basu N, Bates M, Bates A, Batterham R, Baxendale H, Bayes H, Beadsworth M, Beckett P, Beggs M, Begum M, Bell D, Bell R, Bennett K, Beranova E, Bermperi A, Berridge A, Berry C, Betts S, Bevan E, Bhui K, Bingham M, Birchall K, Bishop L, Bisnauthsing K, Blaikely J, Bloss A, Bolger A, Bonnington J, Botkai A, Bourne C, Bourne M, Bramham K, Brear L, Breen G, Breeze J, Bright E, Brill S, Brindle K, Broad L, Broadley A, Brookes C, Broome M, Brown A, Brown A, Brown J, Brown J, Brown M, Brown M, Brown V, Brugha T, Brunskill N, Buch M, Buckley P, Bularga A, Bullmore E, Burden L, Burdett T, Burn D, Burns G, Burns A, Busby J, Butcher R, Butt A, Byrne S, Cairns P, Calder PC, Calvelo E, Carborn H, Card B, Carr C, Carr L, Carson G, Carter P, Casey A, Cassar M, Cavanagh J, Chablani M, Chambers RC, Chan F, Channon KM, Chapman K, Charalambou A, Chaudhuri N, Checkley A, Chen J, Cheng Y, Chetham L, Childs C, Chilvers ER, Chinoy H, Chiribiri A, Chong-James K, Choudhury N, Chowienczyk P, Christie C, Chrystal M, Clark D, Clark C, Clarke J, Clohisey S, Coakley G, Coburn Z, Coetzee S, Cole J, Coleman C, Conneh F, Connell D, Connolly B, Connor L, Cook A, Cooper B, Cooper J, Cooper S, Copeland D, Cosier T, Coulding M, Coupland C, Cox E, Craig T, Crisp P, Cristiano D, Crooks MG, Cross A, Cruz I, Cullinan P, Cuthbertson D, Daines L, Dalton M, Daly P, Daniels A, Dark P, Dasgin J, David A, David C, Davies E, Davies F, Davies G, Davies GA, Davies K, Dawson J, Daynes E, Deakin B, Deans A, Deas C, Deery J, Defres S, Dell A, Dempsey K, Denneny E, Dennis J, Dewar A, Dharmagunawardena R, Dickens C, Dipper A, Diver S, Diwanji SN, Dixon M, Djukanovic R, Dobson H, Dobson SL, Donaldson A, Dong T, Dormand N, Dougherty A, Dowling R, Drain S, Draxlbauer K, Drury K, Dulawan P, Dunleavy A, Dunn S, Earley J, Edwards S, Edwardson C, El-Taweel H, Elliott A, Elliott K, Ellis Y, Elmer A, Evans D, Evans H, Evans J, Evans R, Evans RI, Evans T, Evenden C, Evison L, Fabbri L, Fairbairn S, Fairman A, Fallon K, Faluyi D, Favager C, Fayzan T, Featherstone J, Felton T, Finch J, Finney S, Finnigan J, Finnigan L, Fisher H, Fletcher S, Flockton R, Flynn M, Foot H, Foote D, Ford A, Forton D, Fraile E, Francis C, Francis R, Francis S, Frankel A, Fraser E, Free R, French N, Fu X, Furniss J, Garner L, Gautam N, George J, George P, Gibbons M, Gill M, Gilmour L, Gleeson F, Glossop J, Glover S, Goodman N, Goodwin C, Gooptu B, Gordon H, Gorsuch T, Greatorex M, Greenhaff PL, Greenhalgh A, Greenwood J, Gregory H, Gregory R, Grieve D, Griffin D, Griffiths L, Guerdette AM, Guillen Guio B, Gummadi M, Gupta A, Gurram S, Guthrie E, Guy Z, H Henson H, Hadley K, Haggar A, Hainey K, Hairsine B, Haldar P, Hall I, Hall L, Halling-Brown M, Hamil R, Hancock A, Hancock K, Hanley NA, Haq S, Hardwick HE, Hardy E, Hardy T, Hargadon B, Harrington K, Harris E, Harrison P, Harvey A, Harvey M, Harvie M, Haslam L, Havinden-Williams M, Hawkes J, Hawkings N, Haworth J, Hayday A, Haynes M, Hazeldine J, Hazelton T, Heeley C, Heeney JL, Heightman M, Henderson M, Hesselden L, Hewitt M, Highett V, Hillman T, Hiwot T, Hoare A, Hoare M, Hockridge J, Hogarth P, Holbourn A, Holden S, Holdsworth L, Holgate D, Holland M, Holloway L, Holmes K, Holmes M, Holroyd-Hind B, Holt L, Hormis A, Hosseini A, Hotopf M, Howard K, Howell A, Hufton E, Hughes AD, Hughes J, Hughes R, Humphries A, Huneke N, Hurditch E, Husain M, Hussell T, Hutchinson J, Ibrahim W, Ilyas F, Ingham J, Ingram L, Ionita D, Isaacs K, Ismail K, Jackson T, James WY, Jarman C, Jarrold I, Jarvis H, Jastrub R, Jayaraman B, Jezzard P, Jiwa K, Johnson C, Johnson S, Johnston D, Jolley CJ, Jones D, Jones G, Jones H, Jones H, Jones I, Jones L, Jones S, Jose S, Kabir T, Kaltsakas G, Kamwa V, Kanellakis N, Kaprowska S, Kausar Z, Keenan N, Kelly S, Kemp G, Kerslake H, Key AL, Khan F, Khunti K, Kilroy S, King B, King C, Kingham L, Kirk J, Kitterick P, Klenerman P, Knibbs L, Knight S, Knighton A, Kon O, Kon S, Kon SS, Koprowska S, Korszun A, Koychev I, Kurasz C, Kurupati P, Laing C, Lamlum H, Landers G, Langenberg C, Lasserson D, Lavelle-Langham L, Lawrie A, Lawson C, Lawson C, Layton A, Lea A, Lee D, Lee JH, Lee E, Leitch K, Lenagh R, Lewis D, Lewis J, Lewis V, Lewis-Burke N, Li X, Light T, Lightstone L, Lilaonitkul W, Lim L, Linford S, Lingford-Hughes A, Lipman M, Liyanage K, Lloyd A, Logan S, Lomas D, Loosley R, Lota H, Lovegrove W, Lucey A, Lukaschuk E, Lye A, Lynch C, MacDonald S, MacGowan G, Macharia I, Mackie J, Macliver L, Madathil S, Madzamba G, Magee N, Magtoto MM, Mairs N, Majeed N, Major E, Malein F, Malim M, Mallison G, Mandal S, Mangion K, Manisty C, Manley R, March K, Marciniak S, Marino P, Mariveles M, Marouzet E, Marsh S, Marshall B, Marshall M, Martin J, Martineau A, Martinez LM, Maskell N, Matila D, Matimba-Mupaya W, Matthews L, Mbuyisa A, McAdoo S, Weir McCall J, McAllister-Williams H, McArdle A, McArdle P, McAulay D, McCormick J, McCormick W, McCourt P, McGarvey L, McGee C, Mcgee K, McGinness J, McGlynn K, McGovern A, McGuinness H, McInnes IB, McIntosh J, McIvor E, McIvor K, McLeavey L, McMahon A, McMahon MJ, McMorrow L, Mcnally T, McNarry M, McNeill J, McQueen A, McShane H, Mears C, Megson C, Megson S, Mehta P, Meiring J, Melling L, Mencias M, Menzies D, Merida Morillas M, Michael A, Milligan L, Miller C, Mills C, Mills NL, Milner L, Misra S, Mitchell J, Mohamed A, Mohamed N, Mohammed S, Molyneaux PL, Monteiro W, Moriera S, Morley A, Morrison L, Morriss R, Morrow A, Moss AJ, Moss P, Motohashi K, Msimanga N, Mukaetova-Ladinska E, Munawar U, Murira J, Nanda U, Nassa H, Nasseri M, Neal A, Needham R, Neill P, Newell H, Newman T, Newton-Cox A, Nicholson T, Nicoll D, Nolan CM, Noonan MJ, Norman C, Novotny P, Nunag J, Nwafor L, Nwanguma U, Nyaboko J, O'Donnell K, O'Brien C, O'Brien L, O'Regan D, Odell N, Ogg G, Olaosebikan O, Oliver C, Omar Z, Orriss-Dib L, Osborne L, Osbourne R, Ostermann M, Overton C, Owen J, Oxton J, Pack J, Pacpaco E, Paddick S, Painter S, Pakzad A, Palmer S, Papineni P, Paques K, Paradowski K, Pareek M, Parfrey H, Pariante C, Parker S, Parkes M, Parmar J, Patale S, Patel B, Patel M, Patel S, Pattenadk D, Pavlides M, Payne S, Pearce L, Pearl JE, Peckham D, Pendlebury J, Peng Y, Pennington C, Peralta I, Perkins E, Peterkin Z, Peto T, Petousi N, Petrie J, Phipps J, Pimm J, Piper Hanley K, Pius R, Plant H, Plein S, Plekhanova T, Plowright M, Polgar O, Poll L, Porter J, Portukhay S, Powell N, Prabhu A, Pratt J, Price A, Price C, Price C, Price D, Price L, Price L, Prickett A, Propescu J, Pugmire S, Quaid S, Quigley J, Qureshi H, Qureshi IN, Radhakrishnan K, Ralser M, Ramos A, Ramos H, Rangeley J, Rangelov B, Ratcliffe L, Ravencroft P, Reddington A, Reddy R, Redfearn H, Redwood D, Reed A, Rees M, Rees T, Regan K, Reynolds W, Ribeiro C, Richards A, Richardson E, Rivera-Ortega P, Roberts K, Robertson E, Robinson E, Robinson L, Roche L, Roddis C, Rodger J, Ross A, Ross G, Rossdale J, Rostron A, Rowe A, Rowland A, Rowland J, Roy K, Roy M, Rudan I, Russell R, Russell E, Saalmink G, Sabit R, Sage EK, Samakomva T, Samani N, Sampson C, Samuel K, Samuel R, Sanderson A, Sapey E, Saralaya D, Sargant J, Sarginson C, Sass T, Sattar N, Saunders K, Saunders P, Saunders LC, Savill H, Saxon W, Sayer A, Schronce J, Schwaeble W, Scott K, Selby N, Sewell TA, Shah K, Shah P, Shankar-Hari M, Sharma M, Sharpe C, Sharpe M, Shashaa S, Shaw A, Shaw K, Shaw V, Shelton S, Shenton L, Shevket K, Short J, Siddique S, Siddiqui S, Sidebottom J, Sigfrid L, Simons G, Simpson J, Simpson N, Singh C, Singh S, Sissons D, Skeemer J, Slack K, Smith A, Smith D, Smith S, Smith J, Smith L, Soares M, Solano TS, Solly R, Solstice AR, Soulsby T, Southern D, Sowter D, Spears M, Spencer LG, Speranza F, Stadon L, Stanel S, Steele N, Steiner M, Stensel D, Stephens G, Stephenson L, Stern M, Stewart I, Stimpson R, Stockdale S, Stockley J, Stoker W, Stone R, Storrar W, Storrie A, Storton K, Stringer E, Strong-Sheldrake S, Stroud N, Subbe C, Sudlow CL, Suleiman Z, Summers C, Summersgill C, Sutherland D, Sykes DL, Sykes R, Talbot N, Tan AL, Tarusan L, Tavoukjian V, Taylor A, Taylor C, Taylor J, Te A, Tedd H, Tee CJ, Teixeira J, Tench H, Terry S, Thackray-Nocera S, Thaivalappil F, Thamu B, Thickett D, Thomas C, Thomas S, Thomas AK, Thomas-Woods T, Thompson T, Thompson AAR, Thornton T, Tilley J, Tinker N, Tiongson GF, Tobin M, Tomlinson J, Tong C, Touyz R, Tripp KA, Tunnicliffe E, Turnbull A, Turner E, Turner S, Turner V, Turner K, Turney S, Turtle L, Turton H, Ugoji J, Ugwuoke R, Upthegrove R, Valabhji J, Ventura M, Vere J, Vickers C, Vinson B, Wade E, Wade P, Wainwright T, Wajero LO, Walder S, Walker S, Walker S, Wall E, Wallis T, Walmsley S, Walsh JA, Walsh S, Warburton L, Ward TJC, Warwick K, Wassall H, Waterson S, Watson E, Watson L, Watson J, Welch C, Welch H, Welsh B, Wessely S, West S, Weston H, Wheeler H, White S, Whitehead V, Whitney J, Whittaker S, Whittam B, Whitworth V, Wight A, Wild J, Wilkins M, Wilkinson D, Williams N, Williams N, Williams J, Williams-Howard SA, Willicombe M, Willis G, Willoughby J, Wilson A, Wilson D, Wilson I, Window N, Witham M, Wolf-Roberts R, Wood C, Woodhead F, Woods J, Wormleighton J, Worsley J, Wraith D, Wrey Brown C, Wright C, Wright L, Wright S, Wyles J, Wynter I, Xu M, Yasmin N, Yasmin S, Yates T, Yip KP, Young B, Young S, Young A, Yousuf AJ, Zawia A, Zeidan L, Zhao B, Zongo O. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10:761-775. [PMID: 35472304 PMCID: PMC9034855 DOI: 10.1016/s2213-2600(22)00127-8] [Citation(s) in RCA: 144] [Impact Index Per Article: 72.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 03/23/2022] [Accepted: 03/31/2022] [Indexed: 11/25/2022]
Abstract
BACKGROUND No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge. METHODS The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing. FINDINGS 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters. INTERPRETATION The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials. FUNDING UK Research and Innovation and National Institute for Health Research.
Collapse
|
9
|
El-Kamand S, Steiner M, Ramirez C, Halliday C, Chen SCA, Papanicolaou A, Morton CO. Assessing Differences between Clinical Isolates of Aspergillus fumigatus from Cases of Proven Invasive Aspergillosis and Colonizing Isolates with Respect to Phenotype (Virulence in Tenebrio molitor Larvae) and Genotype. Pathogens 2022; 11:pathogens11040428. [PMID: 35456102 PMCID: PMC9029132 DOI: 10.3390/pathogens11040428] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Revised: 03/26/2022] [Accepted: 03/29/2022] [Indexed: 02/01/2023] Open
Abstract
The fungus Aspergillus fumigatus, the cause of invasive aspergillosis (IA), is a serious risk to transplant patients and those with respiratory diseases. Host immune suppression is considered the most important factor for the development of IA. Less is known about the importance of fungal virulence in the development of IA including the significance of variation between isolates. In this study, isolates of A. fumigatus from cases diagnosed as having proven IA or colonisation (no evidence of IA) were compared in assays to measure isolate virulence. These assays included the measurement of radial growth and protease production on agar, sensitivity to UV light and oxidative stressors, and virulence in Tenebrio molitor (mealworm) larvae. These assays did not reveal obvious differences in virulence between the two groups of isolates; this provided the impetus to conduct genomic analysis. Whole genome sequencing and analysis did not allow grouping into coloniser or IA isolates. However, focused analysis of single nucleotide polymorphisms revealed variation in three putative genes: AFUA_5G09420 (ccg-8), AFUA_4G00330, and AFUA_4G00350. These are known to be responsive to azole exposure, and ccg-8 deletion leads to azole hypersensitivity in other fungi. A. fumigatus virulence is challenging, but the findings of this study indicate that further research into the response to oxidative stress and azole exposure are required to understand the development of IA.
Collapse
Affiliation(s)
- Sam El-Kamand
- Western Sydney University, School of Science, Campbelltown Campus, Campbelltown, NSW 2560, Australia; (S.E.-K.); (M.S.); (C.R.)
| | - Martina Steiner
- Western Sydney University, School of Science, Campbelltown Campus, Campbelltown, NSW 2560, Australia; (S.E.-K.); (M.S.); (C.R.)
| | - Carl Ramirez
- Western Sydney University, School of Science, Campbelltown Campus, Campbelltown, NSW 2560, Australia; (S.E.-K.); (M.S.); (C.R.)
| | - Catriona Halliday
- Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia; (C.H.); (S.C.-A.C.)
| | - Sharon C.-A. Chen
- Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia; (C.H.); (S.C.-A.C.)
- Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW 2145, Australia
| | - Alexie Papanicolaou
- Hawkesbury Institute for the Environment, Western Sydney University, Hawkesbury Campus, NSW 2753, Australia
- Correspondence: (A.P.); (C.O.M.); Tel.: +61-2-4570-1385 (A.P.); +61-2-4620-3446 (C.O.M.)
| | - Charles Oliver Morton
- Western Sydney University, School of Science, Campbelltown Campus, Campbelltown, NSW 2560, Australia; (S.E.-K.); (M.S.); (C.R.)
- Correspondence: (A.P.); (C.O.M.); Tel.: +61-2-4570-1385 (A.P.); +61-2-4620-3446 (C.O.M.)
| |
Collapse
|
10
|
Muñoz-Fernández S, Cebrian L, Thuissard IJ, Steiner M, García-Yubero C, Esteban AV, Sánchez F, Gómez A, Matías MA, Cobo-Ibáñez T, Esteban M, Manceñido N, Pajares R, Arribas MR, Martínez A, Andreu C, Esteban C, Romero L, Navío T. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study. J Clin Rheumatol 2022; 28:e348-e352. [PMID: 33657593 DOI: 10.1097/rhu.0000000000001716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES The aim of this study was to examine the incidence of coronavirus disease 2019 (COVID-19) among patients with immunomediated inflammatory diseases (IMIDs) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) and to evaluate the influence of either IMIDs or related therapies on the incidence and evolution of COVID-19. METHODS This observational, cross-sectional study was conducted from January 31, 2020, to May 15, 2020. Data of 902 patients were obtained from clinical records in hospitals, primary care units, and community pharmacies. Inclusion criteria were adults with IMIDs treated with bDMARDs or tsDMARDs who started therapy 3 months prior to study commencement. Patients with poor adherence to treatments were excluded. COVID-19 was classified as "definitive" (severe acute respiratory syndrome coronavirus 2 polymerase chain reaction [PCR]-positive), "possible" (characteristic symptoms and negative PCR), and "suspected" (characteristic symptoms but PCR not performed). RESULTS COVID-19 was diagnosed in 70 patients (11 definitive, 19 possible, and 40 suspected). The cumulative incidence of definitive COVID-19 was 1.2%. When considering all cases, the incidence was 7.8%. Patients on biosimilars tumor necrosis factor blockers were more likely to have a diagnosis of COVID-19 (odds ratio, 2.308; p < 0.001). Patients on anti-B-cell therapies had a lower incidence of infections (p = 0.046). Low rates of hospitalization (14.3%), pneumonia (14.3%), death (2.9%), or thrombosis (2.9%) were observed, and 94.3% of patients recovered. CONCLUSIONS The cumulative incidence of confirmed cases of COVID-19 was similar to the general population, with generally low hospitalization, intensive care management, and mortality rates. COVID-19 incidence was less frequent in patients with more severe immunosuppression.
Collapse
Affiliation(s)
- Santiago Muñoz-Fernández
- From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - Laura Cebrian
- Rheumatology Section, Hospital Universitario Infanta Leonor
| | | | - Martina Steiner
- From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | | | | | | | - Alejandro Gómez
- From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | | | - Tatiana Cobo-Ibáñez
- From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | | | - Noemí Manceñido
- Gastroenterology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - Ramón Pajares
- Gastroenterology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - María Rosario Arribas
- Gastroenterology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - Alicia Martínez
- Pharmacy Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - Cristina Andreu
- Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid
| | | | - Liz Romero
- From the Rheumatology Section, Hospital Universitario Infanta Sofía, Universidad Europea de Madrid
| | - Teresa Navío
- Rheumatology Section, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
11
|
Steiner M, Del Mar Esteban-Ortega M, Thuissard-Vasallo I, García-Lozano I, Moriche-Carretero M, García-González AJ, Pérez-Blázquez E, Sambricio J, García-Aparicio Á, Casco-Silva BF, Sanz-Sanz J, Valdés-Sanz N, Fernández-Espartero C, Díaz-Valle T, Gurrea-Almela M, Fernández-Melón J, Gómez-Resa M, Pato-Cour E, Díaz-Valle D, Méndez-Fernández R, Navío Marco T, Almodóvar R, García-Saenz MC, Del-Prado-Sánchez C, Muñoz-Fernández S. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients With Ankylosing Spondylitis. J Clin Rheumatol 2021; 27:e307-e311. [PMID: 32091451 DOI: 10.1097/rhu.0000000000001348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVE Ankylosing spondylitis (AS) is an inflammatory disease, and choroidal thickness (CT) has been proposed and evaluated as a potential marker of systemic inflammation associated with AS and other inflammatory diseases. This study compared CT measurements taken from patients with severe AS disease activity without eye inflammation with those taken from healthy subjects. METHODS This cross-sectional, multicenter study compared CT in 44 patients with high AS disease activity, and no history of eye inflammation with CT in 44 matched healthy subjects aged between 18 and 65 years. In the AS group, the correlation between CT and C-reactive protein, human leukocyte antigen (HLA) B27 positivity, disease duration, and disease activity was calculated. RESULTS Mean CT values of patients with AS were significantly higher in the right eye, the left eye, and the thickest choroid eye. The right eye mean CT was 338.3 ± 82.8 μm among patients with AS and 290.5 ± 71.2 μm among healthy subjects (p = 0.005). The left eye mean CT was 339.5 ± 84.7 μm for patients with AS and 298.4 ± 68.9 μm for healthy subjects (P = 0.015). The thickest choroid eye CT was 358.4 ± 82.1 μm among patients with AS and 314.1 ± 65.2 μm among healthy subjects (P = 0.006). We did not find a significant correlation between CT and disease activity, C-reactive protein, human leukocyte antigen B27 positivity, or disease duration. CONCLUSIONS Patients with active AS but without a history of eye inflammation had a thicker choroid than healthy subjects. This finding suggests that CT is a marker of systemic inflammation in patients with inflammatory disease, regardless of known eye symptoms.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - María Gómez-Resa
- Ophthalmology, Hospital Universitario Son Espases, Palma de Mallorca
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
van Loon MH, Bayard NS, Steiner M, Roebers CM. Connecting teachers' classroom instructions with children's metacognition and learning in elementary school. Metacogn Learn 2021; 16:623-650. [PMID: 34867118 PMCID: PMC8616875 DOI: 10.1007/s11409-020-09248-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 10/12/2020] [Indexed: 06/13/2023]
Abstract
Many children have difficulties with accurate self-monitoring and effective regulation of study, and this may cause them to miss learning opportunities. In the classroom, teachers play a key role in supporting children with metacognition and learning. The present study aimed to acquire insights into how teachers' cognitive and metacognitive strategy instruction, as well as teacher-directed and child-centered instructional practices are related to children's self-monitoring accuracy, regulation of study, and learning performance. Twenty-one teachers and 308 children (2nd and 4th grade elementary school) participated. Teachers instructed a secret code task, children had to learn the match between letters of the alphabet and corresponding symbols. Teachers were observed and audio-recordings were made of their instructions. Then, children were asked to (a) make restudy selections, (b) complete a test, and (c) self-monitor test performance. Although teachers both addressed cognitive and metacognitive strategies, they more often instructed children about cognitive strategies. Further, teaching practices were more often teacher-directed than child-centered. Although there were no relations between teachers' instructions for metacognitive strategies and children's outcome measures, teaching cognitive strategies was positively associated with children's performance and self-monitoring accuracy. However, teaching cognitive strategies did not predict effective restudy selections. Rather, child-centered instructions (i.e., giving children autonomy to regulate their own learning) positively predicted children's restudy, and further, children's self-monitoring was more accurate in classrooms where teachers more often used child-centered instructional practices. This seems to imply that not only the content of the instructions itself, but particularly the way these are given, affects children's metacognition.
Collapse
Affiliation(s)
- Mariëtte H. van Loon
- Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, CH-3012 Bern, Switzerland
| | - Natalie S. Bayard
- Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, CH-3012 Bern, Switzerland
| | - Martina Steiner
- Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, CH-3012 Bern, Switzerland
| | - Claudia M. Roebers
- Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, CH-3012 Bern, Switzerland
| |
Collapse
|
13
|
Palmieri C, Linden H, Birrell S, Lim E, Schwartzberg L, Rugo H, Cobb P, Jain K, Vogel C, O'Shaughnessy J, Johnston S, Getzenberg R, Barnette K, Steiner M, Brufsky A, Overmoyer B. 100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Buehler FJ, van Loon MH, Bayard NS, Steiner M, Roebers CM. Comparing metacognitive monitoring between native and non-native speaking primary school students. Metacogn Learn 2021; 16:749-768. [PMID: 34867119 PMCID: PMC8616870 DOI: 10.1007/s11409-021-09261-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 02/10/2021] [Indexed: 06/13/2023]
Abstract
Metacognitive monitoring is a significant predictor of academic achievement and is assumed to be related to language competencies. Hence, it may explain academic performance differences between native and non-native speaking students. We compared metacognitive monitoring (in terms of resolution) between native and non-native speaking fourth graders (~ 10 year olds) in two studies. In Study 1, we matched 30 native and 30 non-native speakers and assessed their monitoring in the context of a paired-associates task, including a recognition test and confidence judgements. Study 1 revealed that recognition and monitoring did not differ between native and non-native speaking children. In Study 2, we matched 36 native and 36 non-native speakers and assessed their monitoring with the same paired-associates task. Additionally, we included a text comprehension task with open-ended questions and confidence judgments. We replicated the findings of Study 1, suggesting that recognition and monitoring do not necessarily differ between native and non-native speakers. However, native speaking students answered more open-ended questions correctly than non-native speaking students did. Nevertheless, the two groups did not differ in monitoring their answers to open-ended questions. Our results indicate that native and non-native speaking children may monitor their metacognitive resolution equally, independent of task performance and characteristics. In conclusion, metacognitive monitoring deficits may not be the primary source of the academic performance differences between native and non-native speaking students.
Collapse
Affiliation(s)
- Florian J. Buehler
- Institute of Psychology, Department for Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Mariëtte H. van Loon
- Institute of Psychology, Department for Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Natalie S. Bayard
- Institute of Psychology, Department for Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Martina Steiner
- Institute of Psychology, Department for Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Claudia M. Roebers
- Institute of Psychology, Department for Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| |
Collapse
|
15
|
Richi P, Yuste J, Navío T, González-Hombrado L, Salido M, Thuissard-Vasallo I, Jiménez-Díaz A, Llorente J, Cebrián L, Lojo L, Steiner M, Cobo T, Martín MD, García-Castro M, Castro P, Muñoz-Fernández S. Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases. Vaccines (Basel) 2021; 9:vaccines9030203. [PMID: 33671007 PMCID: PMC7997274 DOI: 10.3390/vaccines9030203] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 02/19/2021] [Accepted: 02/23/2021] [Indexed: 12/19/2022] Open
Abstract
Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included in this study. Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23. Immune response against pneumococcal serotypes 1, 3, 7F, 14, 19A, and 19F were assessed evaluating functional antibodies by an opsonophagocytosis killing assay (OPKA). In this study, 182 patients with AIID completed the sequential vaccination protocol. Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers. Rituximab was not associated with a worse response when compared with the rest of biological agents. Not glucocorticoids, nor synthetic disease-modifying antirheumatic drugs, interfered with the immune response. OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.
Collapse
Affiliation(s)
- Patricia Richi
- Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, Spain; (A.J.-D.); (M.S.); (T.C.); (S.M.-F.)
- School of Medicine, Universidad Europea, 28670 Madrid, Spain
- Correspondence: (P.R.); (J.Y.)
| | - Jose Yuste
- Spanish Pneumococcal Reference Laboratory, National Center for Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Correspondence: (P.R.); (J.Y.)
| | - Teresa Navío
- Rheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain; (T.N.); (L.C.); (L.L.)
| | | | - Marina Salido
- Rheumatology Unit, Hospital Universitario Infanta Cristina, Parla, 28981 Madrid, Spain; (M.S.); (P.C.)
| | | | - Ana Jiménez-Díaz
- Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, Spain; (A.J.-D.); (M.S.); (T.C.); (S.M.-F.)
| | - Jesús Llorente
- Pharmacy Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, 28702 Madrid, Spain;
| | - Laura Cebrián
- Rheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain; (T.N.); (L.C.); (L.L.)
| | - Leticia Lojo
- Rheumatology Unit, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain; (T.N.); (L.C.); (L.L.)
| | - Martina Steiner
- Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, Spain; (A.J.-D.); (M.S.); (T.C.); (S.M.-F.)
- School of Medicine, Universidad Europea, 28670 Madrid, Spain
| | - Tatiana Cobo
- Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, Spain; (A.J.-D.); (M.S.); (T.C.); (S.M.-F.)
- School of Medicine, Universidad Europea, 28670 Madrid, Spain
| | - María Dolores Martín
- BR Salud Laboratories, Bacteriology Department, San Sebastián de los Reyes, 28702 Madrid, Spain;
| | - Marta García-Castro
- Rheumatology Unit, Hospital del Tajo, Aranjuez, 28300 Madrid, Spain; (L.G.-H.); (M.G.-C.)
| | - Patricia Castro
- Rheumatology Unit, Hospital Universitario Infanta Cristina, Parla, 28981 Madrid, Spain; (M.S.); (P.C.)
| | - Santiago Muñoz-Fernández
- Rheumatology Unit, Hospital Universitario Infanta Sofía San Sebastián de los Reyes, 28702 Madrid, Spain; (A.J.-D.); (M.S.); (T.C.); (S.M.-F.)
- School of Medicine, Universidad Europea, 28670 Madrid, Spain
| |
Collapse
|
16
|
Bayard NS, van Loon MH, Steiner M, Roebers CM. Developmental Improvements and Persisting Difficulties in Children's Metacognitive Monitoring and Control Skills: Cross-Sectional and Longitudinal Perspectives. Child Dev 2021; 92:1118-1136. [PMID: 33529372 PMCID: PMC8248442 DOI: 10.1111/cdev.13486] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
This study investigated age‐dependent improvements of monitoring and control in 7/8‐ and 9/10‐year‐old children. We addressed prospective (judgments of learning and restudy selections) and retrospective metacognitive skills (confidence judgments and withdrawal of answers). Children (N = 305) completed a paired‐associate learning task twice, with a 1‐year delay. Results revealed improvements in retrospective, but not in prospective monitoring and control. Furthermore, control remained suboptimal, seemingly a consequence of overoptimistic monitoring. Both age groups showed stronger monitoring‐based control at the second compared to the first assessment. The comparison with a cross‐sectional sample (N = 144) revealed that improvements in retrospective monitoring can be mainly attributed to naturally occurring development, whereas retrospective control seemed to improve due to increased task familiarity.
Collapse
|
17
|
Steiner M, Huettmann F. Justification for a taxonomic conservation update of the rodent genus Tamiasciurus: addressing marginalization and mis-prioritization of research efforts and conservation laissez-faire for a sustainability outlook. The European Zoological Journal 2021. [DOI: 10.1080/24750263.2020.1857852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- M. Steiner
- Institute for Arctic Biology, Department of Conservation Ecology, EWHALE Lab, University of Alaska Fairbanks, Fairbanks, AK, USA
| | - F. Huettmann
- Institute for Arctic Biology, Department of Conservation Ecology, EWHALE Lab, University of Alaska Fairbanks, Fairbanks, AK, USA
| |
Collapse
|
18
|
Magnes T, Wagner S, Thorner AR, Neureiter D, Klieser E, Rinnerthaler G, Weiss L, Huemer F, Zaborsky N, Steiner M, Weis S, Greil R, Egle A, Melchardt T. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence. ESMO Open 2021; 6:100012. [PMID: 33399078 PMCID: PMC7807834 DOI: 10.1016/j.esmoop.2020.100012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 11/05/2020] [Accepted: 11/10/2020] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND The prognosis of patients with secondary central nervous system lymphoma (SCNSL) is poor and despite massive advances in understanding the mutational landscape of primary diffuse large B-cell lymphoma (DLBCL), the genetic comparison to SCNSL is still lacking. We therefore collected paired samples from six patients with DLBCL with available biopsies from a lymph node (LN) at primary diagnosis and the central nervous system (CNS) at recurrence. PATIENTS AND METHODS A targeted, massively parallel sequencing approach was used to analyze 216 genes recurrently mutated in DLBCL. Healthy tissue from each patient was also sequenced in order to exclude germline mutations. The results of the primary biopsies were compared with those of the CNS recurrences to depict the genetic background of SCNSL and evaluate clonal evolution. RESULTS Sequencing was successful in five patients, all of whom had at least one discordant mutation that was not detected in one of their samples. Four patients had mutations that were found in the CNS but not in the primary LN. Discordant mutations were found in genes known to be important in lymphoma biology such as MYC, CARD11, EP300 and CCND3. Two patients had a Jaccard similarity coefficient below 0.5 indicating substantial genetic differences between the primary LN and the CNS recurrence. CONCLUSIONS This analysis gives an insight into the genetic landscape of SCNSL and confirms the results of our previous study on patients with systemic recurrence of DLBCL with evidence of substantial clonal diversification at relapse in some patients, which might be one of the mechanisms of treatment resistance.
Collapse
Affiliation(s)
- T Magnes
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | - S Wagner
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria
| | - A R Thorner
- Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, USA
| | - D Neureiter
- Department of Pathology, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - E Klieser
- Department of Pathology, Paracelsus Medical University, Salzburg, Austria
| | - G Rinnerthaler
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - L Weiss
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - F Huemer
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
| | - N Zaborsky
- Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - M Steiner
- Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - S Weis
- Division of Neuropathology, Department of Pathology and Neuropathology, Kepler University Hospital and School of Medicine, Johannes Kepler University, Linz, Austria
| | - R Greil
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - A Egle
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria
| | - T Melchardt
- Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.
| |
Collapse
|
19
|
Steiner M, Del Mar Esteban-Ortega M, Thuissard-Vasallo I, García-Lozano I, García-González AJ, Pérez-Blázquez E, Sambricio J, García-Aparicio Á, Casco-Silva BF, Sanz-Sanz J, Valdés-Sanz N, Fernández-Espartero C, Díaz-Valle T, Gurrea-Almela M, Fernández-Melón J, Gómez-Resa M, Pato-Cour E, Díaz-Valle D, Méndez-Fernández R, Navío T, Moriche-Carretero M, Muñoz-Fernández S. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis. J Clin Rheumatol 2020; Publish Ahead of Print. [PMID: 33779125 DOI: 10.1097/rhu.0000000000001458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Choroidal thickness (CT) has been evaluated as a marker of systemic inflammation in ankylosing spondylitis (AS). This study evaluates the CT of AS patients before and after 6 months of biological treatment. METHODS This longitudinal multicenter study evaluated CT in 44 AS patients. The correlations between CT and C-reactive protein (CRP) with disease activity indices were calculated. The concordance between CT and CRP was determined. We assessed factors associated with response to treatment. Clinically important improvement was defined as a decrease in Ankylosing Spondylitis Disease Activity Score of 1.1 points or greater. RESULTS Forty-four eyes in patients aged 18 to 65 years were included. Mean CT values were significantly higher at baseline than after 6 months of treatment (baseline: 355.28 ± 80.46 μm; 6 months: 341.26 ± 81.06 μm; p < 0.001). There was a 95% concordance between CT and CRP at baseline and 6 months. Clinically important improvement was associated with lower baseline CT and age as independent factors (odds ratios, 0.97 [95% confidence interval, 0.91-0.93; p = 0.009] and 0.81 [95% confidence interval, 0.7-0.95; p = 0.005]), with baseline CT of less than 374 μm (sensitivity 78%, specificity 78%, area under the curve 0.70, likelihood ratio 3.6). CONCLUSIONS Choroidal thickness decreased significantly after 6 months of biological treatment in all treatment groups. Choroidal thickness and CRP had a 95% concordance. A high CT was associated with a risk of biological treatment failure. Choroidal thickness can be considered a useful biomarker of inflammation and a factor associated with response to treatment in AS.
Collapse
Affiliation(s)
- Martina Steiner
- From the *Rheumatology Department, Hospital Universitario Infanta Sofía †Biomedical and Health Science Faculty, Universidad Europea ‡Ophthalmology Department, Hospital Universitario Infanta Sofía §Rheumatology Department, Hospital Universitario 12 de Octubre ∥Ophthalmology Department, Hospital Universitario 12 de Octubre, Madrid ¶Rheumatology Department #Ophthalmology Department, Hospital Virgen de la Salud, Toledo **Rheumatology Department ††Ophthalmology Department, Hospital Universitario de Majadahonda ‡‡Rheumatology Department §§Ophthalmology Department, Hospital Universitario de Móstoles, Madrid ∥∥Rheumatology Department ¶¶Ophthalmology Department, Hospital Universitario Son Espases, Palma de Mallorca ##Rheumatology Department ***Ophthalmology Department, Hospital Clínico San Carlos †††Rheumatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Richi P, Martín MD, Andreu-Vázquez C, Jiménez-Diaz A, Steiner M, Muñoz-Fernández S. Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study. Med Clin (Barc) 2020; 156:118-122. [PMID: 32571618 DOI: 10.1016/j.medcli.2020.04.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 03/24/2020] [Accepted: 04/02/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Influenza vaccine is recommended for patients with autoimmune inflammatory diseases (AIID) on biological therapy. OBJECTIVE To evaluate whether serological response to Influenza vaccine obtained in patients on biological therapy is similar to that achieved in patients on synthetic disease-modifying anti-rheumatic drugs (DMARDs) and that obtained in healthy controls. METHODS We designed a cohort study in which patients with AIID, 68 on biological therapy and 46 on synthetic DMARDs, as well as 48 healthy controls, were included and vaccinated during the 2015-2016 influenza season. ELISA was used to measure Influenza antigen (Ag) A and B antibodies, before and after vaccination. RESULTS After vaccination, 88.24% of patients on biologics, 71.74% of those on synthetic DMARDs and 89.58% of healthy controls, presented detectable antibodies against antigen A, while 42.65% of subjects on biologics, 41.30% of those on DMARDs and 54.17% of healthy subjects were seropositive against Ag B. We did not find statistical differences. CONCLUSIONS In our study, biological therapy is not associated with worse serological response.
Collapse
Affiliation(s)
- Patricia Richi
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España; Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España.
| | - María Dolores Martín
- Departamento de Bacteriología, BR Salud Laboratorios, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España
| | - Cristina Andreu-Vázquez
- Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España
| | - Ana Jiménez-Diaz
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España
| | - Martina Steiner
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España; Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España
| | - Santiago Muñoz-Fernández
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España; Facultad de Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, España
| |
Collapse
|
21
|
Esteban-Ortega MM, Steiner M, García-Lozano I, Thuissard-Vasallo I, Moriche-Carretero M, Muñoz-Fernández S. Reproducibility of manual choroidal thickness measurements using optical coherence tomography. ACTA ACUST UNITED AC 2020; 95:379-385. [PMID: 32532593 DOI: 10.1016/j.oftal.2020.03.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2019] [Revised: 03/01/2020] [Accepted: 03/02/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE Spectral-domain optical coherence tomography (SD-OCT) is the most useful tool to measure choroidal thickness (CT). CT may be increased in ocular and systemic diseases. However, there are concerns relating reproducibility and external validity of OCT. The aim of this study was to assess the inter-observer and intra-observer variability of manual OCT measurements. METHODS CT was manually measured in the central choroid of 40 eyes from 21 subjects (11 healthy and 10 with ankylosing spondylitis) using RTVue-100 OCT (Optovue Inc., Fremont, CA, EE.UU.). Measurements were performed by 9 independent ophthalmologists from 6 different centers. To assess the inter-observer variability, the intra-class correlation coefficient (ICC) method was calculated. Also, intra-observer variability was assessed in 2 of the ophthalmologists. RESULTS The mean subfoveal CT was 364.9±85.1μm (range, 170 to 572). The inter-observer ICC was 0.823 (CI 95%, 0.749 to 0.888, p<0.001). The intra-observer ICCs were 0.885 (CI 95%, 0.783 to 0.939, p<0.001) and 0.925 (CI 95%, 0.859 to 0.960. p<0.001). CONCLUSIONS In this study, manual measurements of CT with OCT showed a good concordance. These results suggest that manual OCT is a valid tool for multicenter studies.
Collapse
Affiliation(s)
- M M Esteban-Ortega
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - M Steiner
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España; Sección de Reumatología, Hospital Universitario Infanta Sofía, Madrid, España.
| | - I García-Lozano
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - I Thuissard-Vasallo
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - M Moriche-Carretero
- Sección de Oftalmología, Hospital Universitario Infanta Sofía, Madrid, España; Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España
| | - S Muñoz-Fernández
- Departamento de Medicina, Facultad de Ciencias Biomédicas, Universidad Europea, Madrid, España; Sección de Reumatología, Hospital Universitario Infanta Sofía, Madrid, España
| | | |
Collapse
|
22
|
Steiner M, Esteban-Ortega MDM, Thuissard-Vasallo I, García-Lozano I, García J, Perez-Blazquez E, Sambricio J, García-Aparicio Á, Casco-Silva BF, Sanz J, Valdés-Sanz N, Fernandez-Espartero C, Díaz-Valle T, Gurrea-Almela M, Fernández-Leroy J, Gómez-Resa M, Pato E, Díaz Valle D, Méndez-Fernández R, Navio Marco MT, Muñoz-Fernández S. AB0726 CHOROIDAL THICKNESS IS A BIOMARKER AND CAN PREDICT THE RESPONSE TO TREATMENT IN ANKYLOSING SPONDYLITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Choroidal thickness (CT) has been proposed and evaluated as a potential marker of systemic inflammation associated with inflammatory diseases as Ankylosing spondylitis (AS). Patients with active AS have a thicker choroid than healthy subjects, regardless of eye inflammation. The evolution of choroid after treatment is poorly known.Objectives:This study evaluates the CT of patients with severe AS disease activity before and after six months of biological therapy.Methods:This prospective multicenter study evaluates the CT in 44 patients with high AS disease activity, naïve for biological treatment, and no history of eye inflammation before and after six months of biological therapy, aged from 18 to 65 years. The correlations between the CT and C-reactive protein (CRP) with the disease activity indices and scales as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), night pain and Patient Global Assessment (PGA) were calculated at baseline and after six months of biological therapy. The concordance between the CT and CRP was determined. Finally, we assessed potential predictors of response to treatment. Clinically important improvement was defined as a decrease in ASDAS score ≥ 1.1 points.Results:Globally, 44 eyes of 44 patients aged between 18-65 years were included in the study, 12 (27%) women. The biological treatments prescribed were: Adalimumab 13 (29.5%), Certolizumab 9 (20.5%), Secukinumab 10 (20%), Etanercept 8 (18%), Infliximab 3 (6.8%), and Golimumab 1 (2.2%).Mean CT values were significantly higher at baseline than after six months of treatment (baseline 355.28±80.46 µm; 6 months, 341.26±81.06 µm) (p<0.001).CT decreased both in patients on biological treatment without effect in eye (Secukinumab and Etanecept; p=0.024) and in patients on treatment with effect in eye (other; p=0.005). Also, CRP, BASDAI, night pain and PGA decreased after six months of treatment ((p<0.001, p<0.001, p<0.001, p<0.001). We found a 95% concordance between CT and CRP at baseline and 6 months.Multivariable analysis showed that clinically important improvement was associated with higher CT and age as independent factors (OR 0.97, CI95% 0.91-0.93; p=0.009, and OR 0.81, CI95% 0.7-0.95; p=0.005). Clinically important improvement was associated with basal CT >374 µm (sensitivity 78 %, [CI 95% 60-90], specificity 78% [CI 95% 52-92], area under the curve of ROC, 0.70, likelihood ratio 3.6).Conclusion:CT decreased significantly after six months of biological treatment. CT and CPR had a 95% concordance. A high CT is associated with risk of failure to biological treatment. CT can be considered as a useful biomarker of inflammation and predictor of response to treatment in AS.References:[1]Karkucak M, Kalkisim A, Kola M, et al. SAT0408 anti Tnf-α therapy provides beneficial effects on choroidal thickness increase in patients with active ankylosing spondylitis: a possible mechanism of infliximab effectiveness in suppressing uveitis attacks.Ann Rheum Dis. 2016;75:817.Disclosure of Interests:None declared
Collapse
|
23
|
Richi P, Steiner M, Muñoz-Fernández S. Reply. Med Clin (Barc) 2020; 156:254-255. [PMID: 32359964 DOI: 10.1016/j.medcli.2020.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Accepted: 03/12/2020] [Indexed: 11/17/2022]
Affiliation(s)
- Patricia Richi
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España.
| | - Martina Steiner
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España
| | - Santiago Muñoz-Fernández
- Servicio de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, España
| |
Collapse
|
24
|
Flores-Orozco A, Gallistl J, Steiner M, Brandstätter C, Fellner J. Mapping biogeochemically active zones in landfills with induced polarization imaging: The Heferlbach landfill. Waste Manag 2020; 107:121-132. [PMID: 32279051 DOI: 10.1016/j.wasman.2020.04.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 03/28/2020] [Accepted: 04/01/2020] [Indexed: 06/11/2023]
Abstract
In this study, we investigate the applicability of the Induced Polarization (IP) imaging method to discriminate between biogeochemically active and inactive areas of a landfill. The elevated amount of degradable organic carbon in landfills results in the development of biogeochemical hot-spots associated with high rates of microbial activity and the generation of landfill gas and leachate as metabolic products. Our results demonstrate that the electrical conductivity is mainly sensitive to the increase in the fluid conductivity associated to leachate production and migration. Whereas images of the polarization effect, expressed in terms of the imaginary component (σ″) or the phase of the complex conductivity (ϕ), reveal the potential to characterize variations in the architecture and biogeochemical activity of the landfill. Correspondingly, biogeochemically active zones (leachable TOC contents above 1500 mg/kg dry waste) are related to high polarization values (σ″ > 10 mS/m, ϕ > 40 mrads), whereas low leachable TOC contents (<300 mg/kg dry waste) in the inactive areas are characterized by low polarization values (σ″ < 1 mS/m, 10 < ϕ < 25). Additionally, landfill sections corresponding to construction and demolition waste (CDW), associated to negligible TOC content, exhibit the lowest polarization response (σ″ < 0.1 mS/m, ϕ < 15). We prove that IP imaging is a well-suited method for landfill investigations that permits an improved characterization of landfill geometry, variation in waste composition, and the discrimination between biogeochemically active and inactive zones.
Collapse
Affiliation(s)
- A Flores-Orozco
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria.
| | - J Gallistl
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria
| | - M Steiner
- TU-Wien, Department of Geodesy und Geoinformation, Geophysics Research Division, Austria
| | - C Brandstätter
- TU Wien, Institute for Water Quality and Resource Management, Austria
| | - J Fellner
- TU Wien, Institute for Water Quality and Resource Management, Austria
| |
Collapse
|
25
|
Richi P, Alonso O, Martín MD, González-Hombrado L, Navío T, Salido M, Llorente J, Andreu-Vázquez C, García-Fernández C, Jiménez-Diaz A, Lojo L, Cebrián L, Thuissard-Vasallo I, Martínez de Aramayona MJ, Cobo T, García-Castro M, Castro P, Fernández-Castro M, Illera Ó, Steiner M, Muñoz-Fernández S. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study. Clin Rheumatol 2020; 39:2751-2756. [PMID: 32248433 DOI: 10.1007/s10067-020-05042-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 02/12/2020] [Accepted: 03/10/2020] [Indexed: 01/01/2023]
Abstract
To evaluate the response to hepatitis B virus (HBV) vaccine in patients on biological therapy. Adults with autoimmune inflammatory diseases on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included. Hepatitis B surface antibody (anti-HBs) was measured by ELISA before and after vaccination. Seroconversion was considered when an anti-HBs titer > 10 mIU/mL was achieved. The effect of treatment on the immunoprotective state was studied. The response was compared with that obtained in patients on synthetic disease modifying anti-rheumatic drugs (DMARDs) and healthy controls. A total of 187 patients on biologicals, 48 on synthetic DMARDs, and 49 on healthy controls were analyzed. More than 80% of patients on biologics responded to the vaccine but required more boosters and second vaccine series. Patients who achieved seroconversion were younger than those who did not (47.10 ± 12.99 vs. 53.18 ± 10.54 years, p = 0.012). Being on etanercept or golimumab was associated with seroconversion, while being on rituximab was not. Seroconversion was achieved in 93.75% of patients on synthetic DMARDs and 97.96% of healthy controls. The seroconversion rate in the biologics group was lower than in the synthetic DMARD group (p = 0.043) and tended to be lower than in the healthy group (p = 0.056). In patients on biological therapy, a high rate of HBV vaccine response can be achieved when a complete vaccination schedule is administered. Vaccination while not on biological agents reduces the requirement for boosters and revaccination. Key points: • Patients on biological therapy can achieve high rates of immune response to HBV vaccine when complete vaccination schedules are administered. • However, to achieve such a high seroconversion rate, more boosters and second vaccination series are required. • This supports the proposal already made to provide HBV vaccination to all patients with an autoimmune inflammatory disease after the diagnosis is made and not when the use of a biological treatment is under consideration.
Collapse
Affiliation(s)
- Patricia Richi
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain. .,Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.
| | - Oriol Alonso
- Internal Medicine Service, Hospital Comarcal Sant Jaume de Calella, Calella, Barcelona, Spain
| | - María Dolores Martín
- Bacteriology Department, BR Salud Laboratories, San Sebastián de los Reyes, Madrid, Spain
| | | | - Teresa Navío
- Rheumatology Unit, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Marina Salido
- Rheumatology Unit, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
| | - Jesús Llorente
- Pharmacy Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
| | - Cristina Andreu-Vázquez
- Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - Cristina García-Fernández
- Preventive Medicine Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
| | - Ana Jiménez-Diaz
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain
| | - Leticia Lojo
- Rheumatology Unit, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Laura Cebrián
- Rheumatology Unit, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - Israel Thuissard-Vasallo
- Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | | | - Tatiana Cobo
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.,Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | | | - Patricia Castro
- Rheumatology Unit, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
| | | | - Óscar Illera
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.,Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - Martina Steiner
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.,Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - Santiago Muñoz-Fernández
- Rheumatology Unit, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.,Faculty of Biomedical and Health Sciences. Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| |
Collapse
|
26
|
Cost KT, Unternaehrer E, Jonas W, Gaudreau H, Bouvette-Tourcot A, Steiner M, Lydon J, Szatmari P, Meaney M, Fleming A. Once and Again: Intergenerational Transmission of Parenting. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2017.01.147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
IntroductionAnimal and human studies suggest that individual differences in maternal parenting behaviour are transmitted from one generation to the next.ObjectiveThis study aimed to examine potential psychosocial mechanisms underlying an intergenerational transmission of conceptualization of parenting, including affect, cognition, and parental support.MethodsIn a subsample of 201 first-time mothers participating in the Maternal Adversity, Vulnerability and Neurodevelopment (MAVAN) project, we assessed maternal childhood rearing experiences, using the Parental Bonding Instrument and the Childhood Trauma Questionnaire. At 6 months postpartum, mothers completed questionnaires on parenting stress, symptoms of depression, internalization of maternal care regulation and current relationship with mother and father.ResultsWe found significant direct associations of maltreatment and rearing by the grandmother with parenting stress at 6 months. These associations were mediated through distinct psychosocial pathways: the association of maltreatment on higher parenting stress was fully mediated through more maternal symptoms of depression (z = 2.297; P = 022). The association between sub-optimal rearing provided by the mother and higher parenting stress was mediated through lower internalization of maternal care regulation (z = -2.155; P = 031) and to a lesser degree through more symptoms of depression (z = -1.842; P = 065). Finally, higher quality rearing by the grandfather was indirectly related to lower parenting stress through positive current relationship with the father (z = -2.617; P = 009).ConclusionsThere are distinct pathways by which early experiences manifest in parenting stress. By understanding the structure of dysregulated parenting, clinicians will have practical information to specifically target maternal motivation, social supports, and depressed mood to disrupt maladaptive parenting cognitions and practices.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
27
|
Cézard G, Gruer L, Steiner M, Douglas A, Davis C, Buchanan D, Katikireddi SV, Millard A, Sheikh A, Bhopal R. Ethnic variations in falls and road traffic injuries resulting in hospitalisation or death in Scotland: the Scottish Health and Ethnicity Linkage Study. Public Health 2020; 182:32-38. [PMID: 32151824 PMCID: PMC7294220 DOI: 10.1016/j.puhe.2020.01.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 01/09/2020] [Accepted: 01/23/2020] [Indexed: 02/05/2023]
Abstract
Objectives To investigate ethnic differences in falls and road traffic injuries (RTIs) in Scotland. Study design A retrospective cohort of 4.62 million people, linking the Scottish Census 2001, with self-reported ethnicity, to hospitalisation and death records for 2001–2013. Methods We selected cases with International Classification of Diseases–10 diagnostic codes for falls and RTIs. Using Poisson regression, age-adjusted risk ratios (RRs, multiplied by 100 as percentages) and 95% confidence intervals (CIs) were calculated by sex for 10 ethnic groups with the White Scottish as reference. We further adjusted for country of birth and socio-economic status (SES). Results During about 49 million person-years, there were 275,995 hospitalisations or deaths from fall-related injuries and 43,875 from RTIs. Compared with the White Scottish, RRs for falls were higher in most White and Mixed groups, e.g., White Irish males (RR: 131; 95% CI: 122–140) and Mixed females (126; 112–143), but lower in Pakistani males (72; 64–81) and females (72; 63–82) and African females (79; 63–99). For RTIs, RRs were higher in other White British males (161; 147–176) and females (156; 138–176) and other White males (119; 104–137) and females (143; 121–169) and lower in Pakistani females (74; 57–98). The ethnic variations differed by road user type, with few cases among non-White motorcyclists and non-White female cyclists. The RRs were minimally altered by adjustment for country of birth or SES. Conclusion We found important ethnic variations in injuries owing to falls and RTIs, with generally lower risks in non-White groups. Culturally related differences in behaviour offer the most plausible explanation, including variations in alcohol use. The findings do not point to the need for new interventions in Scotland at present. However, as the ethnic mix of each country is unique, other countries could benefit from similar data linkage-based research. Ethnic inequalities in injuries are demonstrated in Scotland based on a large sample size and a fine ethnic granularity. White minority ethnic groups had the highest risks of fall-related injuries in Scotland. Fall-related injuries were the least likely in the Pakistani population. Ethnic differences in road traffic injuries varied by the type of road user. Ethnic differences in injuries were not explained by socio-economic status or country of birth.
Collapse
Affiliation(s)
- G Cézard
- School of Geography and Sustainable Development, University of St Andrews, St Andrews, UK; Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
| | - L Gruer
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - M Steiner
- Environmental & Occupational Medicine, Section of Population Health, University of Aberdeen, Aberdeen, UK
| | - A Douglas
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - C Davis
- Information Services Division (ISD), NHS National Services Scotland, Edinburgh, UK
| | - D Buchanan
- Information Services Division (ISD), NHS National Services Scotland, Edinburgh, UK
| | - S V Katikireddi
- MRC Social & Public Health Sciences Unit, Evaluation of Social Interventions Programme, University of Glasgow, Glasgow, UK
| | - A Millard
- NHS Health Scotland, Directorate of Public Health Science, Glasgow, UK
| | - A Sheikh
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - R Bhopal
- Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
28
|
Kabai E, Poppitz-Spuhler A, Savkin BT, Steiner M. Retrospective analysis of Sr-90 in roe deer antlers originating from north-west Germany. J Radioanal Nucl Chem 2019. [DOI: 10.1007/s10967-019-06914-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Tucher N, Höhn O, Murthy JN, Martinez JC, Steiner M, Armbruster A, Lorenz E, Bläsi B, Goldschmidt JC. Energy yield analysis of textured perovskite silicon tandem solar cells and modules. Opt Express 2019; 27:A1419-A1430. [PMID: 31684495 DOI: 10.1364/oe.27.0a1419] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Accepted: 07/12/2019] [Indexed: 05/18/2023]
Abstract
Perovskite silicon tandem solar cells combine potentially low production costs with the ability to surpass the efficiency limit of silicon single junction solar cells. Optical modeling and optimization are crucial to achieve this ambitious goal in the near future. The optimization should seek to maximize the energy yield based on realistic environmental conditions. This work analyzes the energy yield of perovskite silicon tandem solar cells and modules based on realistic experimental data, with a special focus on the investigation of surface textures at the front and rear side of the solar cell and its implication for reflection as well as parasitic absorption properties. The investigation reveals a 7.3%rel higher energy yield for an encapsulated tandem cell with a textured front side compared with an encapsulated high efficiency single junction solar cell with 24.3% harvesting efficiency for irradiance data of the year 2014 in Freiburg/Germany.
Collapse
|
30
|
Steiner M, van Loon MH, Bayard NS, Roebers CM. Development of Children's monitoring and control when learning from texts: effects of age and test format. Metacogn Learn 2019; 15:3-27. [PMID: 32226352 PMCID: PMC7089689 DOI: 10.1007/s11409-019-09208-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 08/29/2019] [Indexed: 05/24/2023]
Abstract
This study investigated elementary school children's development of monitoring and control when learning from texts. Second (N = 138) and fourth (N = 164) graders were tested in the middle (T1) and end (T2) of the school year. The study focused on the cross-sectional and longitudinal development of monitoring and control, and aimed to investigate the development of metacognition for two test formats. After reading expository texts, children completed a comprehension test consisting of open-ended and true-false questions. They monitored their test performance by making confidence judgments, and controlled performance by deciding whether to maintain or withdraw their given answers. Overall, monitoring and control accuracy was higher for open-ended questions than for true-false questions. For open-ended questions, results indicated higher metacognitive accuracy for fourth graders than second graders. No such age effects were found for monitoring and control for true-false questions. Longitudinally, children of both age groups improved their monitoring and control accuracy from T1 to T2, for open-ended and true-false questions. For both test types, improvement mainly occurred for the monitoring and controlling of incorrect, rather than correct answers. Additionally, the results indicated inter-individual stability of performance, but no stability of monitoring and control accuracy over time. The findings indicate that developmental as well as task-related factors affect children's metacognitive accuracy.
Collapse
Affiliation(s)
- Martina Steiner
- Institute of Psychology, Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Mariëtte H. van Loon
- Institute of Psychology, Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Natalie S. Bayard
- Institute of Psychology, Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| | - Claudia M. Roebers
- Institute of Psychology, Department of Developmental Psychology, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland
| |
Collapse
|
31
|
Roebers CM, Mayer B, Steiner M, Bayard NS, van Loon MH. The role of children's metacognitive experiences for cue utilization and monitoring accuracy: A longitudinal study. Dev Psychol 2019; 55:2077-2089. [PMID: 31343230 DOI: 10.1037/dev0000776] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although the literature consistently documents strong improvements in metacognitive skills over the elementary school years, relatively little is known about the mechanisms fueling these developments. One factor that is being discussed in the literature and targeted in the present approach is cue utilization. Cue utilization quantifies the degree to which an individual uses mnemonic experiences during task mastery to inform monitoring processes. In the present study, retrieval fluency as a valid and ubiquitous cue during recognition was assessed by recording children's choice latencies in a recognition test and by relating these to confidence ratings. A sample of second graders and fourth graders was assessed 3 times over one year in terms of their recognition performance, the time needed to select an alternative, and their monitoring accuracy. Results revealed age differences in monitoring accuracy, cue utilization, and cue validity. Moreover, while monitoring accuracy increased over time in both age groups, cue utilization increased only in the younger children. Analyses were completed by an individual differences approach showing that cue utilization is a factor driving recognition improvements over time, underlining the importance of metacognitive experiences for development. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
Collapse
|
32
|
Richi P, Martín MD, Navío MT, González-Hombrado L, Salido M, Llorente J, Thuissard-Vasallo I, Alcocer P, Saa-Requejo CM, Jiménez-Diaz A, Cebrián L, Lojo L, García-Castro M, Sanz-Rosa D, Castro P, Fernández-Rodríguez S, Martínez de Aramayona MJ, Steiner M, Cobo T, García-Fernández C, Fernández-Castro M, Illera Ó, Valverde R, Muñoz-Fernández S. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study. Med Clin (Barc) 2019; 153:380-386. [PMID: 31060878 DOI: 10.1016/j.medcli.2019.02.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 02/04/2019] [Accepted: 02/07/2019] [Indexed: 01/25/2023]
Abstract
BACKGROUND AND OBJECTIVES Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine. MATERIAL AND METHODS Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied. RESULTS 253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054). CONCLUSIONS Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.
Collapse
Affiliation(s)
- Patricia Richi
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain.
| | - María Dolores Martín
- Bactereology Department, BR Salud Laboratories, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - María Teresa Navío
- Rheumatology Department, Infanta Leonor University Hospital, Gran Vía del Este 80, 28031 Madrid, Spain
| | - Laura González-Hombrado
- Rheumatology Department, Tajo University Hospital, Av. Amazonas Central s/n, Aranjuez, 28300 Madrid, Spain
| | - Marina Salido
- Rheumatology Department, Infanta Cristina University Hospital, Av 9 de Junio 2, Parla, 28981 Madrid, Spain
| | - Jesús Llorente
- Pharmacy Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Israel Thuissard-Vasallo
- School of Doctoral Studies & Research, Europea University, Calle Tajo s/n, Villaviciosa de Odón, 28670 Madrid, Spain
| | - Patricia Alcocer
- Rheumatology Department, HM Hospital, Avenida de Manoteras n° 10, 28050 Madrid, Spain
| | - Carmen María Saa-Requejo
- Preventive Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Ana Jiménez-Diaz
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Laura Cebrián
- Rheumatology Department, Infanta Leonor University Hospital, Gran Vía del Este 80, 28031 Madrid, Spain
| | - Leticia Lojo
- Rheumatology Department, Infanta Leonor University Hospital, Gran Vía del Este 80, 28031 Madrid, Spain
| | - Marta García-Castro
- Rheumatology Department, Tajo University Hospital, Av. Amazonas Central s/n, Aranjuez, 28300 Madrid, Spain
| | - David Sanz-Rosa
- School of Doctoral Studies & Research, Europea University, Calle Tajo s/n, Villaviciosa de Odón, 28670 Madrid, Spain
| | - Patricia Castro
- Rheumatology Department, Infanta Cristina University Hospital, Av 9 de Junio 2, Parla, 28981 Madrid, Spain
| | - Sandra Fernández-Rodríguez
- Occupational Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - María José Martínez de Aramayona
- Occupational Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Martina Steiner
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Tatiana Cobo
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Cristina García-Fernández
- Preventive Medicine Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Mónica Fernández-Castro
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Óscar Illera
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Ricardo Valverde
- Dermatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| | - Santiago Muñoz-Fernández
- Rheumatology Department, Infanta Sofía University Hospital, Paseo de Europa 34, San Sebastián de los Reyes, 28702 Madrid, Spain
| |
Collapse
|
33
|
Steiner M, Esteban-Ortega MDM, Muñoz-Fernández S. Choroidal and retinal thickness in systemic autoimmune and inflammatory diseases: A review. Surv Ophthalmol 2019; 64:757-769. [PMID: 31034855 DOI: 10.1016/j.survophthal.2019.04.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 04/14/2019] [Accepted: 04/22/2019] [Indexed: 12/22/2022]
Abstract
To identify the risk of relapse and subclinical inflammatory stages of systemic autoimmune diseases, new tools are needed. In the recent years, choroidal thickness and retinal thickness measured with ocular coherence tomography (OCT) have been proposed as an inflammatory marker for different systemic diseases, especially for conditions with a vascular component. Our aim in this article is to review the literature regarding the role of choroidal and retinal thickness as a potential inflammatory marker in systemic autoimmune and inflammatory diseases measured by OCT. Current literature suggests that the choroid of patients thickens in active phases of inflammatory diseases with vascular involvement. This pattern is observed in lupus, systemic sclerosis, Behçet disease, spondylitis, and familial Mediterranean fever. Choroidal thickness may decrease with biological treatments, along with systemic inflammation. Repeated flares and long-term disease, however, may thin the choroid, as a result of prolonged insult to the microvasculature and subsequent atrophy. Less is known about the effect of these diseases on retinal thickness. In summary, choroidal and retinal thickness measured by OCT may be promising markers for inflammation in systemic autoimmune and inflammatory diseases; however, more studies are warranted before generalizing choroidal thickness measurements by OCT as a marker for disease activity. The role of retinal thickness is more unclear due to a lack of studies in this field.
Collapse
Affiliation(s)
- Martina Steiner
- Department of Rheumatology, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.
| | - Maria Del Mar Esteban-Ortega
- Universidad Europea de Madrid, Madrid, Spain; Department of Ophthalmology, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain
| | - Santiago Muñoz-Fernández
- Department of Rheumatology, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain
| |
Collapse
|
34
|
Gampenrieder SP, Angela R, Rinnerthaler G, Hackl H, Steiner M, Pulverer W, Weinhaeusel A, Klinglmayr E, Karl T, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Biomarkers predicting response to bevacizumab containing therapy in metastatic breast cancer (MBC) are of urgent need. In a retrospective single-institution analysis we have previously shown that a 3-gene methylation signature (MLH1,POLKand TMBIM6) could discriminate between responders and non-responders to a bevacizumab-based therapy in two independent cohorts of patients with MBC with an AUC of 0.94 and 0.86, respectively (Gampenrieder SP et al. Theranostics. 2018. 8(8):2278-2288). Here, we present the validation of these findings within the prospective phase III trial TANIA (Vrdoljak E et al. Ann Oncol. 2016. 27(11):2046-52) randomizing 494 patients with HER2-negative MBC to chemotherapy plus bevacizumab or chemotherapy alone for two consecutive treatment lines (second- and third-line). All patients had already received bevacizumab-containing therapy in the first-line setting.
Patients and methods: DNA isolated from archival FFPE tumor samples was available from 200 patients consenting to optional translational research within the TANIA trial. Out of these, 176 samples were collected prior to first-line bevacizumab therapy and were analyzed retrospectively. Sufficient DNA for methylation analysis was available from 124 patients: 64 treated with chemotherapy plus bevacizumab and 60 treated with chemotherapy alone. All samples were isolated from the primary tumor. Quantitative methylation analysis was performed by pyrosequencing on the PyroMark Q24 Advanced System (Qiagen). PFS and OS analyses were performed in both study arms comparing “predicted responders” (PRED_R) versus “predicted non-responders” (PRED_NR) based either on median dichotomization or according to the cutoffs for individual CpG and the combined 3-CpG methylation logistic regression model.
Results:Out of the 124 evaluable patients, 32 (25.8%) were classified as PRED_R and 92 as RED_NR by the 3-gene methylation signature. PRED_R did not have a significantly different second-line PFS (HR 0.95, 95%CI 0.57-1.57; P = 0.84) or OS (HR 0.91, 95%CI 0.51-1.60; P = 0.73) when treated in the bevacizumab-containing study arm compared to PRED_NR. In addition, PRED_R did not show a longer PFS when treated with bevacizumab compared to PRED_R treated with chemotherapy alone (HR 0.95, 95%CI 0.59-1.54; P = 0.83). Furthermore, there was no difference in third-line PFS and the combination of second- and third-line PFS between PRED_R and PRED-NR in the bevacizumab arm. In the control arm, PRED_NR showed a statistically significant shorter PFS compared to PRED_R (HR 0.50, 95%CI 0.22-0.77; P = 0.006), but not OS (HR 0.95, 95%CI 0.51-1.77; P = 0.86).
Conclusion: Our 3-gene methylation signature was not confirmed as predictive biomarker for bevacizumab efficacy in metastatic breast cancer.
(This research project was partially supported by ROCHE Austria GmbH)
Citation Format: Gampenrieder SP, Angela R, Rinnerthaler G, Hackl H, Steiner M, Pulverer W, Weinhaeusel A, Klinglmayr E, Karl T, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-07.
Collapse
Affiliation(s)
- SP Gampenrieder
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - R Angela
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - G Rinnerthaler
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - H Hackl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - M Steiner
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - W Pulverer
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Weinhaeusel
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - E Klinglmayr
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - T Karl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - S Ilic
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - C Hufnagl
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - C Hauser-Kronberger
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - A Egle
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| | - R Greil
- Hemostseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria; University of Salzburg, Salzburg, Austria; Biocenter, Medical University of Innsbruck, Innsbruck, Austria; Center for Health & Bioresources, Business Unit for Molecular Diagnostics, AIT – Austrian Institute of Technology GmbH, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria
| |
Collapse
|
35
|
Dama M, Mahoney JL, Van Lieshout RJ, Frey BN, Steiner M. The Menopause Visual Analogue Scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition. Climacteric 2018; 21:502-508. [DOI: 10.1080/13697137.2018.1495705] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Dama
- Department of Public Health Sciences, University of Toronto, Toronto, ON, Canada
| | - J. L. Mahoney
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
| | - R. J. Van Lieshout
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - B. N. Frey
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - M. Steiner
- Women’s Health Concerns Clinic, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
- Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
36
|
Dewart C, Serpico J, Steiner M, Gallo M. Electronic interventions for changing knowledge, attitudes or practice regarding contraception: a systematic review. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Abstract
SummaryThe effect of vitamin E administration on platelet function was evaluated in a group of normal, healthy volunteers. Platelet aggregation induced by collagen, ADP and epinephrine and platelet adhesion to collagen were measured at weekly intervals in 20 men and 27 women divided into 3 experimental groups of 12 individuals each and one control group of 5 men and 6 women. One experimental group was on a 6-week regimen of vitamin E in increasing dosages (4001.U.-1.2001.U.), the second group received aspirin, 300 mg every other day, and the third group was on a combination of vitamin E and aspirin. In the control group, platelet function was measured at weekly intervals. In women, vitamin E by itself produced a small but significant reduction of collagen-induced platelet aggregation. A similar trend was seen in men. However, the reduction never reached statistical significance. Adhesiveness to collagen was not affected by aspirin ingestion but showed a highly significant reduction in vitamin E and vitamin E + aspirin treated individuals. These results suggest that vitamin E administration could have a beneficial effect in patients suffering from arterial thromboembolic diseases.
Collapse
Affiliation(s)
- M Steiner
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, and Brown University Providence, Rl, U.S.A
| |
Collapse
|
38
|
Abstract
SummaryPools of polymerized and total tubulin were measured in human platelets as a function of free sulfhydryl groups both in acid-soluble and acid-precipitable cell fractions. Changes in free thiols were produced either by storage of platelets at room temperature or by addition of the potent oxidizing agent diazene dicarboxylic acid (diamide) and were correlated with shifts in the dynamic equilibrium between assembled and disassembled microtubules and platelet aggregation. Diamide at concentrations of 0.5 to 5 mM depleted acid soluble SH groups and reduced protein thiols while causing a progressive decrease in polymerized tubulin. Similar changes, although not as severe, were initiated by storage of platelets at room temperature. Platelet aggregation especially that induced by collagen showed a positive correlation with the pool of polymerized tubulin. Our results indicate that the state of oxidation of sulfhydryl groups especially in the acid- precipitable fraction plays an important role in determining the position of equilibrium between polymerized and depolymerized tubulin.
Collapse
Affiliation(s)
- M Steiner
- The Division of Hematology/Oncology, The Memorial Hospital, Pawtucket, and Brown University, Providence, RI, USA
| |
Collapse
|
39
|
Abstract
SummaryEstrogens in high doses have been shown to inhibit, in vitro, the thrombin-neutralizing action of antithrombin III (AT III). In this study we investigate the effect of estrogens on AT III in greater detail. To increase the sensitivity of measurement of AT III activity in the absence of heparin, we have developed an assay system utilizing human platelets, AT III and thrombin. The two proteins derived from human plasma were prepared in high purity. Platelet aggregation was induced by approximately 0.02 NIH U of thrombin. AT III was added in amounts that suppressed 95% of the aggregation-inducing effect of thrombin. Estrogens blocked the thrombin-neutralizing effect of AT III in dose-dependent manner. This effect was shown to be specific for AT III. Neither aggregability of platelets nor aggregating effect of thrombin were affected by the steroid hormone. Evidence for binding of estrogen to AT III was obtained from changes in intrinsic fluorescence of AT III. Activity of AT III was also reduced in increasing order of effectiveness by cholesterol, cortisone, testosterone and progesterone. Our studies suggest a direct effect of estrogens and other steroids on AT III, altering its specific neutralization of thrombin.
Collapse
Affiliation(s)
- H Nagasawa
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - B K Kim
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - M Steiner
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| | - M G Baldini
- The Division of Hematologic Research, Department of Medicine, Brown University at The Memorial Hospital, Pawtucket, Rhode Island, U.S.A
| |
Collapse
|
40
|
Abstract
SummaryThe function of nonimmune IgG associated with platelets is unknown. In a series of experiments we have investigated this problem, relating amount of platelet-associated IgG (PAIgG) to platelet volume, serotonin release, adherence of platelets to monocytes and platelet senescence. Most of these studies were performed with human platelets. Platelets freed of preexisting PAIgG by incubation at 22° C were incubated with IgG in a series of concentrations ranging from 0.4 — 27.0 X10-6 M. The IgG preparations used were demonstrably free of aggregated forms of the protein. The amount of PAIgG bound to platelets was determined by the use of fluorescein isothiocyanate-conjugated anti-IgG antibody (F-anti-IgG antibody) which was quantified in a fluorospectrophotometer. Newly bound IgG was assayed similarly by the use of F-IgG. A dose-dependent increase in platelet volume was associated with the binding of nonimmune IgG by platelets. The process which leveled off at an IgG concentration of 1.2 —1.5 X10-5 M was almost fully reversible and was not due to platelet shape change or aggregation. Release of serotonin from IgG-treated platelets was relatively small but to the extent that it occurred was positively related to the IgG concentration to which platelets were exposed. Adherence to autologous monocytes studied quantitatively by the use of formaldehyde-fixed cells was also positively related to the amount of IgG on the platelets. Normal or IgG-defident serum had a potent inhibitory (noncompetitive) action on the binding of F-IgG and F-anti-human IgG antibody to human platelets. Cohorts of platelets prepared in rabbits during the recovery phase of immunological thrombocytopenia induced by injection of heterologous antiserum, showed an age-dependent increase of PAIgG and of IgG binding. These results suggest that PAIgG plays a role in the clearance of senescent platelets.
Collapse
Affiliation(s)
- K Sugiura
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| | - M Steiner
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| | - M Baldini
- The Division of Hematologic Research, The Memorial Hospital, Pawtucket, R. I., and Brown University, Providence, R. I., U.S.A
| |
Collapse
|
41
|
Abstract
SummaryThe effect of thrombin on the phosphorylating activity of platelet membranes was compared to that of trypsin. Preincubation of non-32P phosphorylated platelet membranes with or without either of these two enzymes resulted in a considerable loss of membrane protein kinase activity which was most severe when trypsin was used. Protein kinase activity and endogenous protein acceptors decreased in parallel. 32P-phosphorylated membranes showed a slow but progressive loss of label which was accelerated by trypsin. Thrombin under these conditions prevented the loss of 32P-phosphate. These results are interpreted to indicate a thrombin-induced destruction of a phosphoprotein phosphatase. The protein kinase activity of phosphorylated platelet membranes using endogenous or exogenous protein substrates showed a significant reduction compared to non-phosphorylated membranes suggesting a deactivation of protein kinase by phosphorylation of platelet membranes. Neither thrombin nor trypsin caused a qualitative change in the membrane polypeptides accepting 32P-phosphate but resulted in quantitative alterations of their ability to become phosphorylated.
Collapse
|
42
|
Sehmbi M, Rowley CD, Minuzzi L, Kapczinski F, Steiner M, Sassi RB, Bock NA, Frey BN. Association of intracortical myelin and cognitive function in bipolar I disorder. Acta Psychiatr Scand 2018. [PMID: 29536533 DOI: 10.1111/acps.12875] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
OBJECTIVE Although cognitive dysfunction persists through affective and euthymic states in bipolar disorder (BD), its neurobiological correlates remain undetermined. We explore whole-cortex intracortical myelin (ICM) and cognition in BD-I and controls. METHODS T1 -weighted images (3T) optimized for ICM measurement were analyzed using a surface-based approach. MRI signal was sampled at cortical mid-depth. Cognitive performance was measured via standardized computerized battery and paper-and-pencil Trails B. RESULTS ICM was associated with verbal memory (VM) in BD throughout a cortical network identified with pertinence to VM function, with strongest effects in left caudal middle temporal cortex and left dorsolateral prefrontal cortex (Pcorrected < 0.05). Subanalyses revealed specific association with correct word recognition, without delay. Processing speed, executive function, and reaction time were also predicted by ICM in BD, but not controls, although this did not survive Bonferroni correction. CONCLUSION This is the first study to show VM association with ICM in BD. ICM has been implicated in the integrity of neural connections and neural synchrony. VM dysfunction is one of the most replicated cognitive abnormalities in BD. Therefore, these results provide a novel mechanism for understanding cognitive dysfunction in BD, which can aid in the development of targeted therapeutics to improve cognitive outcomes in BD.
Collapse
Affiliation(s)
- M Sehmbi
- MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
| | - C D Rowley
- MiNDS Neuroscience Graduate Program, McMaster University, Hamilton, ON, Canada
| | - L Minuzzi
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - F Kapczinski
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - M Steiner
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| | - R B Sassi
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - N A Bock
- Department of Psychology, Neuroscience, and Behaviour, McMaster University, Hamilton, ON, Canada
| | - B N Frey
- Mood Disorders Program, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.,Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
| |
Collapse
|
43
|
Bhopal R, Gruer L, Cézard G, Douglas A, Steiner M, Millard A, Buchanan D, Katikireddi V, Sheikh A. 1.1-O5Mortality, ethnicity and country of birth on a national scale 2001-2013: the Scottish Health and Ethnicity Linkage Study. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky047.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Bhopal
- The University of Edinburgh, United Kingdom
| | - L Gruer
- The University of Edinburgh, United Kingdom
| | - G Cézard
- The University of Edinburgh, United Kingdom
| | - A Douglas
- The University of Edinburgh, United Kingdom
| | - M Steiner
- The University of Aberdeen, United Kingdom
| | - A Millard
- NHS Health Scotland, Edinburgh, United Kingdom
| | - D Buchanan
- Information Services Division, Edinburgh, United Kingdom
| | - V Katikireddi
- MRC Social and Public Sciences Unit, Glasgow, United Kingdom
| | - A Sheikh
- The University of Edinburgh, United Kingdom
| |
Collapse
|
44
|
Gruer L, Millard A, Williams L, Bhopal R, Katikireddi S, Cezard G, Buchanan D, Douglas A, Steiner M, Sheikh A. 3.10-P23All-cause hospitalisation of different ethnic groups: a data linkage cohort study of 4.62 million people in Scotland. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky048.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- L Gruer
- University of Edinburgh, United Kingdom
| | | | | | - R Bhopal
- University of Edinburgh, United Kingdom
| | | | - G Cezard
- University of Edinburgh, United Kingdom
| | - D Buchanan
- Information Services Division, United Kingdom
| | - A Douglas
- University of Edinburgh, United Kingdom
| | - M Steiner
- University of Aberdeen, United Kingdom
| | - A Sheikh
- University of Edinburgh, United Kingdom
| |
Collapse
|
45
|
Katikireddi S, Cezard G, Bhopal R, Williams L, Douglas A, Millard A, Steiner M, Buchanan D, Sheikh A, Gruer L. 4.1-O1Assessing ethnic equity of health policy by studying avoidable mortality, hospitalisations and unplanned readmissions in linked Scottish data. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky047.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Katikireddi
- MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, United Kingdom
| | - G Cezard
- Department of Geography and Sustainable Development (DGSD), Irvine Building, University of St Andrews, Edinburgh, United Kingdom
| | - R Bhopal
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - L Williams
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - A Douglas
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | | | - M Steiner
- Environmental & Occupational Medicine, Section of Population Health, University of Aberdeen, United Kingdom
| | - D Buchanan
- Information Services Division (ISD), NHS National Services Scotland, United Kingdom
| | - A Sheikh
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| | - L Gruer
- Edinburgh Migration, Ethnicity and Health Research Group (EMEHRG), Centre for Population Health Sciences, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, United Kingdom
| |
Collapse
|
46
|
Goldberg H, Stein ME, Steiner M, Sprecher E, Beck D, Kuten A. Consolidation Radiation Therapy following Cytoreductive Surgery, Chemotherapy and Second-Look Laparotomy for Epithelial Ovarian Carcinoma: Long-Term Follow-Up. Tumori 2018; 87:248-51. [PMID: 11695352 DOI: 10.1177/030089160108700407] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background From 1979-1987, 139 stage IC-IV ovarian cancer patients who had undergone cytoreductive surgery received 6-11 cycles of cisplatin and adriamycin. Study design Eighty-four clinically complete responders underwent second-look laparotomy, and 60 of them received consolidation abdominal irradiation. The patients were then followed for a median follow-up of 39 months. Results Five- and 10-year actuarial survival for all patients was 43% and 24%, for no residuum at primary surgery, 80% and 35%, for residual tumor <2 cm, 45% and 35%, and for residual tumor >2 cm, 20% and 4%. Median survival for stage III-IV patients negative at second-look laparotomy was 72 months in irradiated compared to 25 months in non-irradiated patients (P = 0.14) and 77 months in irradiated patients with microscopic disease at second-look laparotomy. Median survival in patients with macroscopic disease at second-look laparotomy was 23.5 months if irradiated compared to 18 months if not (P = 0.05). Conclusions Consolidation whole abdominal irradiation in advanced stages of ovarian cancer may be of value in patients with negative or microscopic disease at second-look laparotomy. Unfortunately, despite the initial survival advantage observed in irradiated patients, owing to late recurrences there was no significant difference in their long-term survival probability.
Collapse
Affiliation(s)
- H Goldberg
- Department of Oncology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, Israel
| | | | | | | | | | | |
Collapse
|
47
|
Stemmer SM, Rizel S, Steiner M, Geffen DB, Soussan-Gutman L, Bareket-Samish A, McCullough D, Svedman C, Nisenbaum B, Ryvo L, Peretz T, Fried G, Rosengarten O, Liebermann N, Ben Baruch N. Abstract P1-07-14: Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In Israel, the RS assay has been reimbursed by Clalit Health Services (CHS, the largest HMO in Israel) since 2006, and the assay is widely used in eligible estrogen receptor (ER)+ patients. Notably, ER+ breast cancer patients have a protracted risk of recurrence with approximately half of all distant recurrences occurring after 5 years from diagnosis. The goal of the current ongoing analysis was to investigate early (≤5 years) and late (>5 years) distant recurrence in N0/N1mi ER+ HER2-negative breast cancer patients who were RS-tested through CHS.
Methods: This analysis of the CHS registry included breast cancer patients with ER+ HER2-negative N0/N1mi disease who underwent RS testing from 1/2006 (CHS approval of the assay) through 1/2009. Data sources included CHS claims arms (for patient/tumor characteristics), Teva Pharmaceuticals (for tumor characteristics, RS result), and medical records (for treatment/recurrence/survival). The study was approved by the institutional review boards of the CHS Community Division and was granted a waiver for obtaining patient consent.
Results: The analysis included 1026 patients with median (interquartile range) follow up of 9.3 (8.8-10.2) years. Most patients were females (99%). Median (range) age was 59 (25-84) years; 92% had N0 and 8% had N1mi disease; 14%, 52%, and 16% had grade 1, 2, and 3 tumors, respectively (grade information was not available for 18% of patients); median (range) tumor size was 1.5 (0.3-6.5) cm. The majority of patients (78%) had invasive ductal carcinoma and 12% had invasive lobular carcinoma. Overall, 489 patients (48%) had RS<18, 434 (42%) had RS 18-30, and 103 (10%) had RS≥31. The use of adjuvant CT was consistent with the RS result: 3%, 27%, and 90% of RS<18, RS 18-30, and RS≥31 patients, respectively. Overall, 25 distant recurrences were reported within 5 years of RS testing: 5 (1.0%) in RS<18 patients, 9 (2.1%) in RS 18-30 patients, and 11 (10.6%) in RS≥31 patients. In the first 5 years, breast cancer-specific death was reported in 8 patients including 3 (0.7%) with RS 18-30 and 5 (4.9%) with RS≥31 results. Among N0 patients with RS 11-25 who did not receive adjuvant CT (n = 540), 5 (0.9%) distant recurrences and one (0.2%) breast cancer death were reported within 5 years of RS testing. Analysis of 'late' recurrences and breast cancer-specific death (from 5 to 9.3 years of follow-up) is ongoing.
Conclusions: These will be the first late recurrence data from over 1000 patients for whom the RS result was used in real-life clinical decision making. Consistent with previous analyses of the CHS registry, CT use was appropriately based on the RS result, and the recurrence/survival outcomes (for the first 5 years) demonstrated the prognostic performance of the RS. Distant recurrence and breast cancer death data beyond 5 years will be presented at the meeting.
Citation Format: Stemmer SM, Rizel S, Steiner M, Geffen DB, Soussan-Gutman L, Bareket-Samish A, McCullough D, Svedman C, Nisenbaum B, Ryvo L, Peretz T, Fried G, Rosengarten O, Liebermann N, Ben Baruch N. Real-life analysis evaluating >1000 N0/N1mi estrogen receptor (ER)+ breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score (RS) result: Clinical outcomes with median follow up of > 9 years [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-14.
Collapse
Affiliation(s)
- SM Stemmer
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - S Rizel
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - M Steiner
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - DB Geffen
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - L Soussan-Gutman
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - A Bareket-Samish
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - D McCullough
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - C Svedman
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - B Nisenbaum
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - L Ryvo
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - T Peretz
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - G Fried
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - O Rosengarten
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - N Liebermann
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| | - N Ben Baruch
- Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Oncotest Division, Teva Pharmaceutical Industries, Ltd, Shoham, Israel; BioInsight Ltd, Zichron Yaakov, Israel; Genomic Health Inc., Redwood City; Meir Medical Center, Kfar Saba, Israel; Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Rambam Health Care Campus, Haifa, Israel; Oncology Institute, Shaare Zedek Medical Center, Jerusalem, Israel; Community Division, Clalit Health Services, Tel Aviv, Israel; Kaplan Medical Center, Rehovot, Israel
| |
Collapse
|
48
|
Wolf M, Twaroch TE, Huber S, Reithofer M, Steiner M, Aglas L, Hauser M, Aloisi I, Asam C, Hofer H, Parigiani MA, Ebner C, Bohle B, Briza P, Neubauer A, Stolz F, Jahn-Schmid B, Wallner M, Ferreira F. Amb a 1 isoforms: Unequal siblings with distinct immunological features. Allergy 2017; 72:1874-1882. [PMID: 28464293 PMCID: PMC5700413 DOI: 10.1111/all.13196] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/25/2017] [Indexed: 12/24/2022]
Abstract
Background Ragweed pollen represents a major allergy risk factor. Ragweed extracts contain five different isoforms of the major allergen Amb a 1. However, the immunological characteristics of Amb a 1 isoforms are not fully investigated. Here, we compared the physicochemical and immunological properties of three most important Amb a 1 isoforms. Methods After purification, the isoforms were physicochemically characterized, tested for antibody binding and induction of human T‐cell proliferative responses. Their immunological properties were further evaluated in vitro and in vivo in a mouse model. Results Amb a 1 isoforms exhibited distinct patterns of IgE binding and immunogenicity. Compared to Amb a 1.02 or 03 isoforms, Amb a 1.01 showed higher IgE‐binding activity. Isoforms 01 and 03 were the most potent stimulators of patients’ T cells. In a mouse model of immunization, Amb a 1.01 induced higher levels of IgG and IgE antibodies when compared to isoforms 02 and 03. Interestingly, ragweed‐sensitized patients also displayed an IgG response to Amb a 1 isoforms. However, unlike therapy‐induced antibodies, sensitization‐induced IgG did not show IgE‐blocking activity. Conclusion The present study showed that naturally occurring isoforms of Amb a 1 possess different immunogenic and sensitizing properties. These findings should be considered when selecting sequences for molecule‐based diagnosis and therapy for ragweed allergy. Due to its high IgE‐binding activity, isoform Amb a 1.01 should be included in diagnostic tests. In contrast, due to their limited B‐ and T‐cell cross‐reactivity patterns, a combination of different isoforms might be a more attractive strategy for ragweed immunotherapy.
Collapse
Affiliation(s)
- M. Wolf
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | | | - S. Huber
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. Reithofer
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Steiner
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
- Laboratory for Immunological and
Molecular Cancer Research; Paracelsus Medical University; Salzburg Austria
| | - L. Aglas
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. Hauser
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - I. Aloisi
- Department of Biological, Geological, and Environmental Sciences; University of Bologna; Bologna Italy
| | - C. Asam
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - H. Hofer
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - M. A. Parigiani
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - C. Ebner
- Allergy Clinic Reumannplatz; Vienna Austria
| | - B. Bohle
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - P. Briza
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - A. Neubauer
- Biomay AG; Vienna Competence Center; Vienna Austria
| | - F. Stolz
- Biomay AG; Vienna Competence Center; Vienna Austria
| | - B. Jahn-Schmid
- Department of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Wallner
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| | - F. Ferreira
- Department of Molecular Biology; University of Salzburg; Salzburg Austria
| |
Collapse
|
49
|
Lyons R, Turner SL, Walters AM, Kisser R, Rogmans W, Larsen B, Valkenberg H, Bejko D, Bauer R, Steiner M, Ellsaesser G. Identifying injury related inequalities using data from the European Injury Data Base (IDB). Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- R Lyons
- Swansea University, Swansea, UK
| | | | | | | | | | - B Larsen
- National Institute of Public Health, Odense, Denmark
| | - H Valkenberg
- Consumer Safety Institute, Amsterdam, Netherlands
| | - D Bejko
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - R Bauer
- Austrian Road Safety Board, Vienna, Austria
| | - M Steiner
- Austrian Road Safety Board, Vienna, Austria
| | - G Ellsaesser
- State Office of Occupational Safety, Consumer Protection and Health, Brandenburg, Germany
| |
Collapse
|
50
|
Turner SL, Walters AM, Kisser R, Rogmans W, Larsen B, Valkenberg H, Bejko D, Bauer R, Steiner M, Ellsaesser G, Lyons R. Measuring the burden of injury across Europe. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx187.370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | - B Larsen
- National Institute of Public Health, Odense, Denmark
| | - H Valkenberg
- Consumer Safety Institute, Amsterdam, Netherlands
| | - D Bejko
- Luxembourg Institute of Health, Luxembourg, Luxembourg
| | - R Bauer
- Austrian Road Safety Board, Vienna, Austria
| | - M Steiner
- Austrian Road Safety Board, Vienna, Austria
| | - G Ellsaesser
- State Office of Occupational Safety, Consumer Protection and Health, Brandenburg, Germany
| | - R Lyons
- Swansea University, Swansea, UK
| |
Collapse
|